A Toxicity study on Pañcacūta Meḻuku by Jeeva Nandhini, R
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kaḻaṟci tailam fow;rp ijyk; 
kānta centūram fhe;j nre;J}uk; 
kānta raca villai fhe;j ur tpy;iy 
kantaka cuṭar tailam fe;jf Rlu; ijyk; 
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meḻuku nkOF 
muka vātam Kfthjk; 
muruṅkaippaṭṭai cāṟu Kuq;if gl;il rhW 
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Toxicity, the single word can alarm the whole population into fear. But in reality 
what does the word toxicity refer to? Dr.Jaising P Modi, the author of “A Textbook of 
Medical Jurisprudence and Toxicology” connotes toxicity as unwanted bad effects 
created by certain substances and it can be trivial to grave(1). In reality, almost all the 
substances from plants, animals, minerals, metals or any other sources will show 
toxicity above a certain threshold limit. A popular saying in Tamil — aḷavukku mīṟiṉāl 
amirtamum nañcu which means even elixir turns poisonous when taken in excess 
vouches this. This is also corroborated by descriptions of Paracelsus, a 16thcentuary 
physician, considered to be the first one to incorporate heavy metal-based drugs in 
western medical history. At 
present, a substance is 
deemed to be toxic (despite its 
proven medicinal values), if the threshold limit is very low and was always looked upon 
as a potential threat. For instance, some plants such as Aconitum ferox, seeds of Datura 
sps, Strychnos nux-vomica, Abrus precatorius etc and few metals such as Arsenic, 
Lead, Mercury, Cadmium etc. show a significant toxic effects even at very low doses. 
(2)Nevertheless, these so-called toxic substances have several centuries of usage for its 
medicinal values and contribute to the significant portion of all traditional medical 
systems (3)(4). However, after the dominance of western bio-medicine over other 
medical systems since the second half of 20thcentury, the righteous usage of all 
substances with toxic nature declined due to the reduction in number of traditional 
practitioners. Although, after the invention of various extraction and isolation 
techniques in later part of the 20thcentaury, the active ingredients were separately 
isolated from the potentially toxic ingredients in plants and medical usage of many 
plants with toxic nature has been regularized. But the medical use of metal-based 
substances is still debated due to the very limited understanding about the 
pharmacokinetics of these metals and frequent reports of toxicity associated with its 
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 2 Introduction 
usage. While there is no denying that these substances with low threshold toxic limit 
may become potentially fatal, its fabulous contribution in traditional healthcare should 
also be acknowledged. Most of the metals in general, and mercury in particular were of 
high concern in recent past for its usage in traditional medicine due to the various toxic 
reports associated with them(5).  
When we look in to the historical usage of mercury, it has its strong roots in 
almost all the civilizations. It is best known for Egyptians and Greeks before 2500 BC 
and for Indian and Chinese civilization before 2000 BC(6). Since 500 BCE Greeks used 
inorganic mercury in the form of ointments to treat skin disorders (7)(7).  Egyptians 
used cinnabar in cosmetics(8) and also for preserving the dead bodies as it delays 
decomposition of the body(9), resists insects and other microorganisms(10). Later, they 
started using this in paintings for its insect and microorganism repelling property to 
maintain the colour and texture of paintings for a long period (1). Chinese believed that 
mercury enhances the longevity (elixir) of their life, and to treat skin disorders(11). 
Apart from this they also used mercury as an aphrodisiac, sedative and contraceptive in 
women (12). 
 
After the invention of barometer by Torricellinin 1643 and thermometer by 
Fahrenheit in 1720, mercury became inevitable part of research and medical field 
(13)(14)(6). In 17th century, Mercuric nitrate was adopted in belt and hat making 
process in France and followed by England, USA, Italy, Spain, Russia. Between 1760 
and 1820, industrial revolution burst out and mercury demand has increased.  This 
revolution has revamped the history of mercury usage and it is widely used as 
explosives and detonators in the form of mercury fulminate.In 1829, mercuric 
poisoning symptoms was observed largely among the Hatters, who were working in a 
Belt and Hat Manufacturing company, Russia.In the year 1860, an article was published 
regarding the mercury poisoning as “Mercurial disease among Hatters”(15). It 
explained the forms, usage and toxic effects of mercury to the loud.Apart from this, 
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gold amalgam (an alloy with mercury) thatwas widely used in gilding was found to be 
the cause for numerous casualties among the workers(16). 
Since 1930, Thimerosal (form of ethyl mercury) was used as the most common 
preservative in vaccines, serums, anti-venoms, antigens, antibodies and bio products 
(17)(18). In 1956, most of the population in fisherman families in Minamata and 
Niigata bay of Japan were found to be affected by severe mercury poisoning 
characterized bysevere neurological defects. An industry manufacturing acetaldehyde 
using mercury catalyst located in Minamata that was dumping its industrial waste in to 
river beds was found to be the reason behind this tragedy(14). It took almost twelve 
years for the government to recognize the cause behind this tragedy.Following that 
WHO started creating awareness about methyl mercury consumption among the 
population. Almost 15 years after Minamata incident, in 1971 imported wheat seeds in 
Iraq caused a drastic mass poisoning among 7000 persons resulting in 500 mortalities 
(19).Upon investigation, methyl mercury used as a preservative for seed for of its strong 
fungicidal action was found to be major culprit. Twenty-five years later, in 1997, Karen 
E. Wetterhahn, a toxic metal specialist was accidentally poisoned by the dimethyl 
mercury due to unintended penetration into palms via her protective gloves. As the 
prevalence of occupational exposure gradually raised in later part of twentieth century, 
research for other alternatives for mercury-based products such as fluorescent bulb, 
battery etc. became popular (20)(21). 
By the end of 20th century, due to various reports of occupational toxicity and 
environmental pollution, the direct usage and exposure of mercury was regulated in 
many countries(21). ATSDR (Agency for Toxic Substances and Disease Registry)an 
US based organization found in 1985, for the documentation of the individual 
toxicological profile of the metallic and chemical substances declare most of the metals 
as toxic and numbered mercury at number three next to lead and arsenic in ATSDR 
2017 Toxic substance Priority List (22)(23). The Food and Drug Administration 
modernization Act of 1997, regulated the usage of certain products containing mercury 
including thimerosal(18). By the year 1999, the government sector amended that 
mercury containing products were restricted in manufacturing and some of the most 
important products were manufactured with certain modified formulation.  
The roots of mercury usage in Indian sub-continent were very much evident 
from the works of Dr. Richard S Weiss and Prof. David Gordon White. In most of the 
instances, it’s been viewed as a substance of immortality and elixir of life. 
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Indian medical systems in general and Siddha in particular advocates the use of 
mercury for almost all type of ailments, though it’s been most often indicated for its 
aphrodisiac nature and its potential in management of skin and joint disorders. This 
system elaborates the individual action of Pañcacūtam and its toxic symptoms along 
with specific antidotes. After certain outbreaks of mercury, it has been using with 
stringent safety protocols as per WHO guidelines. Even though in the year 2004, Robert 
K Saper and team reported thatamong the 14 samples out of 70 Ayurvedic formulations 
purchased online (27 manufacturing companies) and showed higher levels of mercury, 
lead or arsenic than permissible limits. This created a huge impact in health policies of 
European countries resulting banning of the drugs listed by Saper(24).This created a 
fear among public in consumption of any herbo-metallic traditional drug. Hence in this 
study an attempt was made to have a complete contemporary understanding of a herbo-
metallic drug Pañca cūta meḻuku (PCM). 
 
 
 
Aim: 
This study aims to evaluate the toxicity effect of Pañca cūta meḻuku. in experimental 
animals. The following objectives were followed in order to attain the aim of the study. 
Primary objective: 
 Preparation and Characterization of Pañca cūta meḻuku. 
 Establish the safety profile and toxic effects of Pañca cūta meḻuku. 
Secondary objective: 
 In order to attain the primary objectives, the secondary objectives were framed. 
 Identification, collection and authentication of raw materials. 
 Purification of raw materials and preparation of Pañca cūta meḻuku. 
 Characterization of Pañca cūta meḻuku as per PLIM guidelines. 
 Instrumentation analysis of PCM with FTIR, XRF and XRD. 
 Evaluation of acute oral toxic effect of PCM in rat models as per OECD 425 
guidelines. 
 Evaluation of 28-days repeated oral toxicity of PCM in rat models as per 
OECD 407 guidelines.
Aim and Objectives 1-A 
  
 
Siddha pharmacology (kuṇapāṭam) refers metal and minerals as tātu carakkukaḷ and 
classify them into 225 substances: 11 ulōkam: metals and its ores, 25 uppu: water-
soluble salts that emit vapour on heating, 64 pāṭāṇam: water insoluble inorganic 
substances that emit vapour on heating, 5 pañca cūtam: mercury and its salts and 120 
uparacam: water insoluble inorganic substances that do not emit vapour on heating. 
Classical Siddha texts describes about 64 drug variants among which 32 are internal 
and 32 are external(25).Pañca cūtam includes five forms of mercury: iracam, liṅkam, 
pūram, vīram and iraca centūram indicated in Siddha literatures for treatment of 
various ailments such as infectious diseases, rheumatic disorders, liver and respiratory 
disorders and in allergic conditions.There are many variants of Pañca cūtam based 
formulations in Siddha system such as kaṭṭu, kalaṅku, vaṭṭu, centūram, paṟpam,meḻuku, 
kuḻampu, māttirai,etc. (25)Few of them are listed in table 2.1. Each of these variants 
will have many formulations (E.g.: There are more than 50 different centūram prepared 
from liṅkam alone), which will result in infinite number of Pañca cūtam formulations.  
Similarly, there are many different types of Pañcacūtam based formulations 
mentioned in various Siddha literatures and there is colossal difference between them 
in preparative procedures and ingredients involved in trituration. Some formulations 
include only trituration of Pañcacūtams with specific plant extracts followed by 
calcinations (26). Some formulations require multiple calcinations at each and every 
stage of trituration(25). In some formulations, apart from Pañcacūtams, many other 
metal/mineral ingredients were added along with different plant extracts for trituration 
followed by single or multiple calcinations(3). Depending on the nature of the 
procedures and total number of calcinations involved, it may take few months to few 
years to prepare a single variant of Pañca cūtams based formulations. As there is no 
notable contemporary literature pertaining to the physio-chemical nature and biological 
activity any of these formulations is available, it is very difficult to understand the 
difference/similarity between these formulations.So exploring the science behind all 
Pañcacūtam based formulations in a single study is practically impossible. Hence 
PCM, a formulation that has all Pañcacūtams were considered for the present study. 
Review of Literature  2 
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Formulation variant Name of the formulation 
Kaṭṭu 1. Liṅka Kaṭṭu,  
2. Vīra Kaṭṭu,  
3. Pūra Kaṭṭu,  
4. Iraca Kaṭṭu. 
Centūram 1. Caṇṭamāruta Centūram 
2. Maṇṭūra Centūram 
3. Kāṭikkāra Centūram 
Mai 1. Nanti mai  
Paṟpam 1. Veḷḷi paṟpam  
2. Pūra Paṟpam 
Karuppu 1. Paṭṭu karuppu  
2. Kastūri karuppu  
Meḻuku 1. Iraca kanti meḻuku  
2. Mahā Vīra Meḻuku 
3. Nava uppu meḻuku  
4. Vāṉ meḻuku  
Kuḻampu 1. Akastiyar kuḻampu  
2. Jāti jampīra kuḻampu  
3. Viṣak kuḻampu  
Māttirai 1. Pāla cañcīvi māttirai  
2. Gorojanai Māttirai 
3. Uruttira pairavam  
4. Aṣṭa pairavam  
Eṇṇey(Internal) 1. Pūra Eṇṇey 
2. Kantaka cuṭar tailam 
Eṇṇey (External) 1. TuvarEṇṇey 
2. Karappāṉ tailam  
Pataṅkam 
1. Paṟaṅkippaṭṭai Pataṅkam 
2. Tirimūrtti Pataṅkam 
 
A comprehensive literature search revealed few formulations similar to that of 
PCM. A formulation named ‘Civappu meḻuku’ isprepared withPañcacūtams (iracam, 
liṅkam, pūram, vīramandiraca centūram), Ōmam (Carum copticum), cittiramūlam vēr 
(root of Plumbago zeylanica), cīṉākkāram (Alum)and pūnīṟu (Fuller’s earth) as major 
ingredients and is indicated for the treatment of viṣapēti, carvāṅkavali, caṉṉi, 
jalatōṣam, cayittiyam, mantam, ajīraṇak kaḻiccal, vayiṟṟu uppucam andIcivu. Even 
though,Civappu meḻuku has all forms of iracam, similar to that of PCM, the preparative 
protocol and indications are distinctively different from PCM. Apart from this, different 
variants of PCM could also be noted in Siddha texts.  
Aṉupōkavaittiyanavanītam, part-7, describes a PCM formulation withvīram, 
iraca karpūram, liṅkam, nellikkāy kantakam, iracam, muruṅkaippaṭṭai cāṟu, Tāyppāl, 
honeyas major ingredients. In this, instead of iracacentūram,nellikkāy kantakamis 
included and is indicated for form indicated for naccu kaḻiccal (viṣa pēti), curam, caṉṉi 
in dosage 1-2 ariciyeṭai (65-130 mg) with butter, palm jiggery as vehicle.  
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Aṉupōkavaittiya navanītam also describes another PCM formulation with same 
with purified iracam, iraca karpūram, vīram, cūṭaṉ, paccaik kaṟpūram and claims to 
curecaṉṉi,cayittiyam, naccu kaḻiccal, makappēṟṟukkuppiṉ caṉṉi when administered in 
1-2 ariciyeṭai (65-130 mg)dosage with butter or palm jiggery as adjuvant.  Here out of 
the five components ofpañcacūtam, iracacentūram and liṅkam were replaced with 
cūṭaṉ (Camphor) and paccaikkaṟpūram (Borneo camphor). Moreover, none of the 
organic ingredients are included in this preparation. 
A formulation in cikiccairatṉatīpam depicts vaalairacam, liṅkam, pūram, 
vīramandiraca centūram along with cērāṅkoṭṭai tailam, veḷḷai pūṇṭu tailam and 
ciṟṟaṇṭa tailam (3 tailam were taken together in equal quantity) as its ingredients. This 
PCM is specially indicated for various disorders ininfants and children: curam, vayiṟṟu 
uppucam, kuṭaiccal, muka vātam, Icivu, piṭippu and iḷampiḷḷai vāyu at a dosage 
ofpayiṟu piramāṇam (42 mg) with mother’s milk as vehicle, twice a day for 3 days. 
This should be administered with a strict food restriction. In case of infants, 
feeding mother should follow food restrictions. In case of adults, restriction should be 
based on severity of disease. If severity is high, tamarind should be restricted or else 
fried salt and fried tamarind should be advised.  
Mercury-review: 
Mercury exists in three oxidation states such as metallic, mercurous, mercuric form. 
Generally toxicity of mercury results by the presence of no. of mercuric ions binds to 
sulfhydryl groups of enzymes. In 1990, WHO limited the intake of inorganic mercury 
about 4µg/day. Some of the traditional system were used elemental and inorganic forms 
of mercury since the ancient such as Santeria, Espiritismo, Siddha and Ayurveda 
system(27). Mercury causes its toxic effect in neurological, renal, reproductive, 
immunological, respiratory and dermatological and also in developmental levels. The 
severity of toxicity depends on the chemical form and route of exposure. In general it 
mainly induces oxidative stress which eventually leads to enzymatic damage, 
membrane rupture and oxidation of biomolecules(28).  
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Metallic mercury: 
Elemental or metallic mercury represented as Hg. In environment, mercury is released 
by various industrial activities such as pharmaceuticals, mining, industrial waste 
incineration and agriculture. 
Source of exposure: 
The main source of metallic mercury vapour exposure in humans is from occupation 
and dental amalgam (50% of metallic mercury)(29). 
Uses: 
Mainlyused as cathartics (accelerates defecation) and industrial products 
(thermometers, sphygmomanometer and batteries)(30). 
Absorption:  
It is poorly absorbed via gastrointestinal tract but 75-85% of vapour absorbed readily 
through mucus membrane to lungs especially causes damage to alveolar membrane and 
can passes blood brain barrier and placental barrier and cause damage to the target 
organs.(30) 
Excretion takes place via sweat, saliva, urine and feces. 
In the environment, the exposure of metallic Hg can persists for more than 4 years in 
air. 
Action in human body: 
Thehalf-life time of metallic mercury is 18 hours. 
These ions in the blood stream transforms into inorganic mercury ions when it oxidized 
by catalase enzyme in tissues and this transformation limits the absorption of mercury 
into cell membrane as it is lipophilic in nature and readily diffusible into biological 
membrane and blood brain barrier. Brain is the target organ with oxidation reaction into 
divalent mercury. 
Toxic symptoms: 
It is reported that occupational exposure increase the concentration of mercury in blood 
to 18 nmol/L and on the other hand, the removal of dental amalgam makes the plasma 
concentration of mercury to range of 5 nmol/L.Through the dental amalgam fillings, 
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the released mercurial concentration ranges approximately 4-5 µg/day. Alsoit is 
reported that each amalgam releases 3-17 µgof mercury vapour per day.(29)Thus on 
comparing the occupational exposure, dental amalgam can exhibit long term exposure 
with trivial symptoms.  
Its vapour causes temporary respiratory problems (bronchitis, asthma). It targets the 
tertiary and quaternary protein and disrupts the membrane potential and calcium 
homeostasis. At last free radicals were produced when the cell integrity is affected. 
Also intervenes in the process of transcription and translation. High level exposure 
causes lung damage, nausea, vomiting, diarrhoea, palpitation, skin rashes and increased 
blood pressure. 
When once exposed to vapour, it deposits in brain with considerable amount and cause 
severe toxicity primarily in the brain and also induce severe pneumonia and sometimes 
fatal.Experimental studies revealed that occupational exposure affects central nervous 
system and the dental amalgam exhibits toxicity in kidney function. 
Occupational exposure of elemental mercury leads to chronic poisoning with the 
following symptoms: 
o Metallic taste in saliva 
o Mucosal inflammation 
o Gingivitis and stomatitis  
o Nephrosis with albuminuria, hypoproteinaemia and edema 
o CNS involvement induces 
o Tremor (bilateral intension tremor, initially in fingers, lips, eyes and 
progresses with painful spasms in extremities. 
o Mercurial erethism characterized by behaviour and personality changes 
with irritability, excitement, sleep disorder, depression and loss of self-
control and confidence. 
o General symptoms: weakness, tired, weight loss and anorexia. 
o Repeated vapor exposure in children causes scarlet skin discoloration (pink 
disease/acrodynia) along with perspiration, tachycardia, increased blood 
pressure, sleeplessness and mood swings(31). 
Some of the autopsy findings of dental amalgam bearers shows the presence of mercury 
about 2-12 fold in tissues than others. An animal experiment shows a significant 
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difference in concentration of mercury in brain as 10 times (7) increase than divalent 
mercury. 
Inorganic mercury: 
Inorganic mercury compounds are formed when it binds to some elements such as 
chlorine,sulphur or oxygen.These composition forms mercuric / mercurous salts such 
as mercuric chloride, Mercurous chloride,mercuric sulphide. Among those mercuric 
sulphide is also known to be cinnabar, which has been used since2000 years in Chinese 
traditional medicine and Indian traditional medicine (Siddha, Ayurveda). 
Source of exposure: 
Indirectly oxidation of mercury and demethylation of methyl mercury by intestinal 
micro flora sources the form of inorganic mercuric salts.(15) 
Uses: 
Inorganic mercury used in medicine preparation and in cosmetics preparation (soap, 
skin cream – 6-10% of mercuric chloride)(8)(7).  Even it has been used in infant teeth 
powder, worm infestation drugs. 
Mercurous chloride is also known to be calomel, was used as diuretics, antiseptics, skin 
ointments laxatives in medical history since ancient period. 
Mercuric chloride holdsa history in medical system with its disinfectant and antiseptic 
activity.(5) 
Absorption:  
Ingested inorganic mercury shows 7-15 % of absorption through gastro intestinal 
tract.(30) 
Sometimes these compounds were inhaled in the form of dust from the environment 
via lungs but this doesn’t shows any significant toxic difference. 
Cinnabar is properly absorbed via gastro intestinal tract ranges from 0.1%-0.2% and 
has low bio- availability than mercuric chloride (10).These are less lipid soluble in 
nature and thus cant able to cross blood brain barrier and placental barrier. An 
experiment of external application in guinea pigs shows absorption of 2-3% of dose 
within 5 hours. 
Excretion occurs through sweat, saliva, urine and feces. 
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Action in human body:  
The half-life period of inorganic mercury is estimated to be 58 days.(32)According to 
brain it is estimated for several years. 
Inorganic mercury can cause toxicity by means of oral administration and methyl 
mercury exposure.In human body,intestinal bacteria converts methyl mercury into 
inorganic mercuric salts and deposited in kidney. 
Once enters the body, the mercurous ion dissociates into uncharged mercury Hg◦ and 
the mercuric ion.(17) 
Toxic symptoms: 
Toxic exposure of mercuric chloride is higher than mercurous chloride. 
EPA and IARC declares that mercuric chloride as carcinogenic. Mercury poisoning is 
said to be acrodynia or pink disease(33). In general, increased exposure causes brain 
function alteration and few symptoms such as shyness, tremors, irritability, memory 
problems and visual and auditory disturbances.(30) 
Effects on CVS: 
 Neurotoxicity is the primary effect caused by mercuric exposure and 
subsequently it produces cardio toxicity.(34) 
Till 2000, the effect of mercury on cardio vascular system was unknown but minamata 
diseased patients suspected with myocardial infarction, coronary disease and other 
cardiovascular disease as their cause of death.(35)(36)(37)(38) 
 Acute toxic effects causes endothelial dysfunction and reduces nitric oxide and its 
bioavailability. The reduction of nitric oxide increases free radicals in the blood vessels. 
Chronic toxic effects causes severe endothelial damage and free radicals production in 
aorta, branches of mesenteric arteries and basilar arteries. 
The main link observed on the effect of mercury on experimental animal shows 
between cardiovascular disease and hypertension with depressed myocardial 
contractility. But the toxic effect of mercury doesn’t affect systolic pressure 
Effect on Blood vessels: 
In blood, initially it binds to sulfhydryl groups of erythrocytes and plasma proteins. It 
denature the proteins, inactivate enzymes and breakdown cell membranes (34)(38). 
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Recent year studies shows that it acts on the endothelium by reducing the nitric oxide 
and availability and thus increasing oxidative stress. 
Atherosclerosis is the major effect caused by oxidative stress in vessels especially in 
aorta(28). Detailed study on vessels shows peripheral and pulmonary vasoconstriction. 
Effect on endocrine receptors: 
It causes significant reduction in T3 and T4 and increased TSH. 
Effect on reproductive system: 
Several animal experiments reported that inorganic form of mercury can develops 
testicular toxicity which includes reduction in spermatogenesis, induce androgen 
deficiency, alters the reproductive behaviour with oxidative stress (28)and lipid 
peroxidation of testicular membrane, affect leydig cells to reduce testosterone level and 
decreasing the LH (Luteinising hormone) and FSH (Follicular stimulating 
hormone).(39) But an experimental study with certain phyto therapeutic anti-oxidants 
shows significant reduction of toxic effects against mercury induced toxicity. Thereby 
Moringa oleifera reduces the lipid peroxidation in testicular membrane. (40) 
Effects on CNS: 
It induces neuronal degeneration and excitability which interacts with N-methyl-D-
aspartate (NMDA) receptors.(13) 
Because of neurotoxic compound, it cause damage to microtubules and mitochondria. 
It affects intracellular calcium homeostasis, alters protein phosphorylation, damages 
cell structure, interrupts the cell cycle and binds to cysteine or methionine rich proteins. 
In specific methyl mercury acts on neuron and inhibits the uptake of glutamate by 
astrocytes, leads to increased concentration of glutamate in extracellular fluid. 
Glutamate targets N-Methyl-D-Aspartate (NMDA) receptors and increases the level of 
sodium and calcium in neuronal cells. 
Effect on Immune system: 
It causes immune dysfunctions with hypersensitivity reactions (asthma, dermatitis, 
Tcell suppression, NK cell suppression and lymphocyte defect). Impaired immune 
system results in Kawasaki disease (31) which is characterized by photophobia, fever, 
pharyngitis, palpitation and Skin rashes. 
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Effects on Kidneys: 
In kidney, heavy metals (mercury) primarily alters the permeability and absorption of 
epithelial cells results in proteinuria and kidney dysfunction.Nephrons plays a major 
role in active transport of mercury and other heavy metals. The route of exposure in 
renal cells is from luminal membranes in proximal tubule and sometimes through 
organic anion transporters of baso-lateral membrane.(41) 
Chronic low dose exposure causes lesions in tubular, interstitial and glomerular parts. 
Inorganic chronic mercuric exposure targets Kidney with high concentration and 90% 
of absorption in proximal tubules of kidney and causes fibrotic changes in glomeruli, 
deposition of Ig G, IgM and C3 in basement membrane of glomerular. (30) 
Oxidative stress is the important mechanism in cellular damage. An experiment in male 
Sprague-Dawley rats shows a significant reduction in the activities of certain 
antioxidant enzymes in the renal cortex such as superoxide dismutase, catalase, GSH 
peroxidase and GSH disulphide. Also oxidative stress can cause damages in glomeruli, 
interstitial tubule and renal vasculature.(28) 
It can also leads to acute tubular necrosis, immunological glomerulonephritis, nephrotic 
syndrome. 
Effects on GIT: 
The toxic symptoms of inorganic salt occurs in two different phases. First phase occurs 
soon after the ingestion, the corrosive nature of salts causes burning sensation in the 
chest, discolouration of mucous membranes, gastro intestinal pain and sometimes 
vomiting, profuse bloody diarrhoea can lead to hypovolemic shock and death. It causes 
severe enterocyte protein precipitation in gut mucosa. 
Inorganic salts have been commonly used in medicine especially calomel as purgative 
in the form of ‘blue pill’. Though calomel has low solubility and significantly produces 
less toxicity than mercuric chloride. 
Organic mercury: 
 Organic Mercury also called as organometallic compound which results from 
the organic functional group such as Methyl mercury, Ethyl methyl or Phenyl group. 
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Source of exposure: 
mercuric ions in the environment by microorganisms present in soil and water.The 
aquatic microorganisms with The common form of organic Hg is methyl and is formed 
by methylation of inorganic methylated Hg is the only source of prey for certain small 
fishes (Tura, shark) and they were consumed by large fishes and finally humans were 
tempted to have fish as their protein diet.(42) Sometimes if methylmercury exists in 
nature, it may be from methylation of inorganic mercury by aquatic sulphatereducing 
anaerobic bacteria.(32) 
Uses: 
 Since the ancient it was used as antiseptics, diuretics and also pesticides .Since 
1930, Thimerosal an organic mercurial preservative to prevent microbial contamination 
in vaccines and serums.(18) 
History events: 
Thimerosal: 
Ethyl mercury, the most used preservative as Thimerosal since 1930 in vaccines and 
bio products. Approximately, it weighs with 50% of mercury and widely used to avoid 
microbial contamination in children vaccines, serums and all biological drugs.It is 
reported that a vaccine contains 0.01%thimerosal which means to be 50 micrograms of 
mercury approximately per 0.5 ml dose. 
The public Health Services (including the FDA, National Institute of Health (NIH), 
CDC and so..,) reviewed the usage and effects of thimerosal in children’s which results 
that there was no health issue but they decided to minimize the cumulative exposure of 
mercury in children to avoid the cumulative toxicity exposure of mercury in lifetime. 
After the invention of Thimerosal, subjected to numerous elaborate studies and finally 
implement with high effectiveness in preventing contamination of bacteria and fungi in 
vaccines and cause no ill effects. 
Minamata disease: 
In japan, mercury in the industrial wastes dissolves into minamata Bay and cause severe 
toxicity in the year 1956.After that incident, the methyl mercury toxicity is also named 
to be minamata disease.Ecosystem plays a predominant role in developing toxicity in 
humans. 
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Once, it dissolves into Bay water, the aquatic microorganisms (certain Bacteria) 
consumes the industrial waste along with Hg and then the inorganic mercuric salts 
intoorganic mercury by methylation process. 
Industrial waste             Aquatic microorganisms           fish         Human          Toxic 
Symptoms 
At the time of minamata disease outbreak, approximately 2252 patients were 
diagnosed, 1043 were died of minamata disease. 
The aetiology was not known until the death of cats ensured with similar symptoms 
equivalent to the symptoms of methyl mercury administration at a range of 1mg/kg of 
cat’s body weight and also certain organs such as brain, liver, kidneys and hair were 
noted with high concentration of deposition. 
Absorption& excretion: 
About 95% methyl mercury absorption takes place via gastro intestinal tract and within 
30 hours.  
90% excretion occurs through bile and feces, 10% in urine.Once it is secreted in bile, 
it completes the entero-hepatic cycle when reabsorbs into blood stream.Its elimination 
undergoes first order Kinetics. 
Action in human body: 
This can easily pass through biological membranes, blood brain barrier and placental 
barrier since they are lipophilic in nature.(43) 
The half-life of ethyl mercury is about one-third longer than methyl mercury (about 70 
days).(32)Once it enters blood stream, reacts with catalase and sulfhydryl group and 
distributed in heart, liver,kidney, brain, placenta, foetus especially in peripheral nerves 
and bone marrow. 
Approximately thimerosal weight with 50% of mercury and widely used to avoid 
microbial contamination in children, serums and all biological drugs. In the body, it 
metabolises into ethyl mercury and thiosalicylate and readily eliminated and may 
sometimes with mild toxicity but yet not reported. Ethylmercury converts into inorganic 
mercury and causes damages to brain cells. 
In animal experiments the compound methyl mercury causes neurological alterations 
with increased reactive oxygen species. 
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Toxic symptoms: 
Organic mercuric poisoning causes depression, memory impairment, tremor, fatigue, 
head ache, hair loss, etc. Methyl mercury is declared to be carcinogenic by EPA and 
IARC. Since it is a neurotoxic compound, it causes mitochondrial damage, microtubule 
damage and lipid peroxidation and finally it gives way to serotonin, glutamate and 
aspartate accumulation. 
Immediate within 3 months of exposure, patients were diagnosed with acute and sub-
acute poisoning, reported with symptoms such as constriction of vision, Ataxia, tremor, 
dysarthria with auditory and sensory disturbances. 
Pathologically, it is characterized with cell damage in cerebral and cerebellar cortex, 
vision centre, auditory centre,pre and post central cortex (Sensory and motor centre) 
and noted that atrophy of cerebellum and demyelination of nerve fibres (20). And 
certain symptoms occurs after the onset of acute poisoning such as hypertension, 
hypersalivation, paraoxysmal symptoms, pyramidal symptoms and strabismus. 
 In 1959, a previousstudy report elucidated the concentration of mercury of organs such 
as liver, brain and kidney approximately ranges 22.0 to 70.5 ppm, 2.6 to 24.8 ppm 
and21.2 to 14.00 ppm respectively in persons who were died in minamata outbreak.  
The exposure of methyl mercury in infants causes cerebral palsy and its concentration 
in umbilical cord seems high level which develops congenital minamata disease with 
atrophy and hypoplasia of brain cortex. 
A most important high toxic organic mercury is considered to be dimethyl mercury, 
used for chemical analysis in the laboratories. After an incident that few drops of 
dimethyl mercury penetrates through the gloves to toxic metal specialist in the year 
1997.Until six months from the time of exposure, it doesn’t shows any symptoms and 
followed sever toxicity, coma and death. Then the use in laboratories are strictly 
banned. 
The toxic effect of methyl mercury targets central nervous system substantially the 
developing brain than the mature organs. Its latent period varies depending on the dose 
and period of exposure. Paraesthesia is the initial symptom of low dose exposure and 
progresses to cerebellar ataxia which results due to the loss of granular cells.(30) 
Until 1970 methyl mercury and ethyl mercury were used for multiple purposes. After 
the issue of Iraq mass poisoning with 500’s of death by the usage of wheat grains which 
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preserved with fungicide (methyl mercury and ethyl mercury exhibits anti-fungal 
activity), the both were banned from usages.(19) 
                   The US Environmental Protection Agencies endorsed a reference value of 
mercury concentration in blood (5.8 ng/ml) and WHO recommends a reference range 
of mercury concentration in hair (<6 µg/g ) and considered below this level mean to be 
safe. 
Some reports showed that there is increased concentration of mercury in hair which 
reaches 150 ug/g for the people who were inhabited in coastal areas where, the main 
source of dietary protein is fish. 
It deposits in maximum concentration in almost all tissues of the body, approximately 
5% in blood and 10% in brain. 
On viewing the concentration in blood compartment, the red blood cells carries 20 times 
than plasma .Also Methyl mercury can able to crosses the blood brain barrier and the 
placental barrier.Thus the concentration in foetal brain is 5-7 times than that of maternal 
blood.And exposure can cause accumulates in growing scalp hair.The most common 
biological indicator for the exposure of mercury is hair and blood. 
Mercury sulphide: 
It is also known to be Cinnabar.Cinnabar is the only form of inorganic form which has 
been used since2000 years ago in medicine.Mercury sulphide is a form of divalent 
mercury and follows the mechanisms of distribution and metabolism but there is a 
significant difference in absorption and bioavailability.(44)The rate of absorption from 
gastro intestinal tract is estimated to be 0.2% and it deposition in tissues is 
approximately 10-100 fold less than mercuric chloride. On comparing mercuric 
chloride, the bioavailability decreases with 30-60 fold and thus is has been used high 
in treating diseases since the past in traditional system of medicine. (10) 
Still cinnabar has been used in Traditional Chinese medicine with 11-13% range in the 
treatment of insomnia, anxiety and depression but it seems to be 110,000 times higher 
than the allowable dose recommended by European Drug and Food Standards.(45) 
Mercury poisoning:  
It occurs in two phases as acute and chronic. The generally mercuric ion binds 
with sulfhydryl group of enzymes and cellular proteins, nucleic acids and mitotic 
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apparatus interfering with enzyme and cellular transport functions. It is rapidly 
converted into mercuric ions leads to renal tubular damage. (41) 
Acute poisoning: 
Acute exposure toelemental mercury vapour may cause corrosive bronchitis 
with fever, chills and dyspnoea. It may progress to pulmonary oedema and fibrosis. 
Sometimes clinical features similar to Kawasaki disease (mucocutaneous lymph node 
syndrome) especially in children. 
Symptoms:- 
 Acrid metallic taste, constriction in the throat, hoarse voice, mouth and tongue shows 
greyish white coating, vomit contains greyish slimy mucoid material with blood and 
shreds of mucous membrane. Circulatory collapse occurs. If survives, sometimes 
symptoms extend after 3 days such as glossitis, ulcerative gingivitis, loosening of teeth 
and necrosis of jaw. In 2-3 days renal tubular necrosis with polyuria, albuminuria, 
uraemia and acidosis. It produces dysentery ulceration with colonic mucosal 
hemmorhage.  
Chronic poisoning: 
Chronic poisoning of mercury is known to be Hydrargyrism. This may results from 
continuous accidental absortion, excessive therapeutic use, recovery from a large dose, 
externally used for a long time. 
Symptoms: 
It leads to classic triad of gingivitis and salivation, tremors and neuropsychartic 
changes. Earlier symptoms are blur line at the junction of teeth, gum inflammation, 
gastrointestinal disturbances, loss of weight and chronic kidney inflammation with 
progressive uraemia. Tremors called to be Danbury tremors occurs first in hands and 
progress to lips and tongue and finally to legs and arms. In advanced condition known 
as hatters shakes or glass-blowers shakes. The most severe form is concussio 
mercurialis, a condition when no activity is possible. Renal damage results in 
membranous glomerulonephritis with fatty cast in urine. 
Mercurial erethism is seen in mirror manufacturing units which includes anxiety, 
depression, timidity, delusions, hallucinations or suicidal melancholia or manic 
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depressive pshychosis (mad hatter), emotional instability, insomnia and loss of 
memory.  
Mercuria lentis is a peculiar eye change due to exposure to vapour of mercury. Due to 
brownish deposit of mercury through the cornea on the anterior lens capsule.  
Acrodynia or pink disease (generalised body rash) thought to be an idiosyncratic 
hypersensitivity reaction particularly in children. The onset is insidious with anorexia, 
insomnia, skin rash, photophobia, sweating, paraesthetic with peeling of skin. 
General treatment protocol: 
 Removal of patient from further exposure 
 Demulcents 
 Saline purgatives 
 Oral hygiene 
 Chelation therapy (D-Penicillamine) 
 For organic mercurial chelation is not effective. 
Even though most of the researches were done in modern period, an ancient 
system of medicine called Siddha system of medicine eventually elaborates a substance 
in all aspects such as character, medicinal properties, growth, toxicological, adverse 
effect and the antidote. Especially mercury and its compounds were illustrated with a 
specific name ‘panchasootham’ which includes mercury, mercurous chloride, mercuric 
chloride, mercury suphide (artificial) and mercury sulphide (natural).the characters and 
medicinal properties with toxicological symptoms are described below. 
The most specific names of rasam which is repeatedly used since ancient to till date 
are: 
 “MwpNa #jkJ Ie;J tpjkhFk; 
 mjd; tpguNk njd;dpyiwiaf;NfS 
 CwpNa urnkd;Wk; uNre;jpunkd;Wk;  
 cw;w ghuj nkd;WQ; #jnkd;Wk; 
 kPwpNa kprpufnkd;iwe;J khr;R” 
- Nghfh; 7000 2k;fhz;lk; 
1. ,urk; 
2. ,uNre;jpud; 
3. #jk; 
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4. kprufk; 
5. ghuk; 
Itpj urj;jpd; gz;G (General properties of five forms of mercury): 
 “jq;fpaNjhH urj;jpDil tz;zq;NfS 
 jdpapuj;j epwkhfj; jSf;Fj; jhdha; 
 kq;fpaNjhH Njhlkw;W urhadKkhfp 
 -------------------------------------------------------------“ 
,urk;> ghujk;> rPtd;tpe;J vdg;gLk; ,j;jhJ ghlhz njhFg;gpy; gpwg;G 
ghlhzkhfTk;> itg;G ghlhzkhfTk; $wg;gl;Ls;sJ. (Nghfh; 7000) 
The above quote explains that each form of mercury shows a uniqueness in their 
colour, texture and character.  
Rit : mWRit (,dpg;G) 
tPhpak; : ntg;grPjk; 
gphpT :  JizkUe;jpd; gphpT 
nra;if : cly;Njw;wp> cly; cukhf;fp> kyk;Nghf;fp> gpj;jePH mfw;wp> 
tPf;fKUf;fp> ckpo;ePH ngUf;fp> rpWePH ngUf;fp> Nkfehrdp 
Even though each of them were contaminated with other metals and some substances 
by source. So purification is considered to be the essential part prior to medicine 
preparation. And the Siddha system of medicine elucidates the contaminants of merury 
briefly in Gunapadam Thathu-Jeevam literature. 
The contaminants and its remedy as per Siddha literature (Njhlq;fs;): 
 Njhlq;fis ,urj;jpd; eQ;R Njh\q;fshf fUJfpd;wdh;.  ,jpy; 
rl;ilfs; (ftrk;) vd;W xUtifAk; cs;sJ. ,urj;jpd; Njhlk; vz; 
tifahfTk;> ,urj;jpd; rl;il vO tifahfTk; tpsf;fpAs;sdh;. 
Njiuah; $Wk; vz;tifj; Njhlq;fSk; mjd; Neha;fSk; 
1. rh;g;gk;  - nfhg;gsk; 
2. tq;fk;  - Fl;lk; 
3. fe;jp  - mf;fpdp 
4. td;dp  - vhpr;ry; 
5. rhQ;ryk;  -  NfhJepwk; 
6. kyk;  - tpe;Jel;lk; 
7. fhsk;  - ,wj;jy; 
8. ke;jk;  - %Hr;ir 
mfj;jpah; $Wk; VO Njh\q;fSk; mjd; Neha;fSk; 
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1. ehfk;  -  JHf;fe;jk; 
2. tq;fk;  - Fl;lk; 
3. fe;jp  - jhfk; 
4. td;dp  - jhJ el;lk; 
5. rhQ;ryk;  -  caph;Nghf;fy; 
6. tplkk;  - tplg;gpzp 
7. Nyhfk;  - Nkhfk; 
mfj;jpah; kw;Wk; Njiuah; $w;wpiz xg;gpl;L ghHf;f> 4 Njh\q;fs; xw;Wikahf 
$wg;gl;L tpsf;fpAs;sdh;.  mtw;wpYk; mjw;fhf $wp Nghe;j Neha; epiy 
khWgl;lNghjpYk; tq;fj;jpd; Njhlk; epiyahd Neha; epiy nfhz;L 
tpsf;fg;gLfpwJ. 
 ,J kl;Lky;yhJ fPo;fhZk; rpy E}w;fspYk; Njhlq;fs; gw;wp 
tpthpj;Js;sdh;. 
1. Njiuah; fhpry; 300 
2. Nghfh; 7000 
3. jpU%yh; 600 
mtw;iw ePf;Fk; Kiwik gw;wpAk; ciuj;Js;sdh;.(remedy to remove the 
contaminants): 
1. ehfk;: ,ur vilf;Fg; gjpdhnwil> nrq;fy;J}s;> kQ;rs; J}s; 
,itfis xd;wd;gpd; xd;whfg; Nghl;L> vYkpr;rk; gor;rhw;why; xUehs; 
miuj;Jg; Gspj;j jz;zPhpy; fOtpdhy; ehf Njhlk; ePq;Fk;. 
2. tq;fk;: tprhyk; (flk;G) mopQ;rpy; Nth; Nghl;Lg; gor;rhw;why; xU ehs; 
miuj;Jf; fhbePuhy; fOt Ntz;Lk;. 
3. kyk;: ,ye;ijNth; Nrh;j;Jg; gourj;jhy; xU ehs;  miuj;Jf; fhb 
ePuhy; fOt Ntz;Lk;. 
4. mf;fpdp: rpj;jpu %yg;gl;ilr; Nrh;j;Jg; gourj;jhy; miuj;Jf; fhbapdhy; 
fOtNtz;Lk;. 
5. rhQ;ry;ak;;: f&T+kj;ij Nth; Nrh;j;Jg; gourj;jhy; miuj;J fhbapdhy; 
fOt Ntz;Lk;. 
6. tplk;: jphpgiyr; #uzk; Nrh;j;Jg; gor; rhw;wpdhy; miuj;Jf; fhbapdhy; 
fOt Ntz;Lk;. 
7. fphp: jphpfLFr; #uzQ; Nrh;j;Jg; gor;rhw;why; miuj;Jf; fhbapdhy; 
fOt Ntz;Lk;. 
8. mrf;ahf;dp: neUQ;rpy; #uzk; Nrh;j;Jg; gor;rhw;why; miuj;Jf; 
fhbapdhy; fOtNtz;Lk;. 
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ghjurj;jpd; nghJf;Fzk; 
 “tpopNeha; fpue;jpFd;kk; nka;r;#iy Gz;Fl; 
 lopfhypy; tpe;Jtpdhy; mj;ij – topaha; 
 GhpA tpjp ahJ GhpapNdh nay;yhk; 
 ,hpA tpjp ahJ kpy;iy” 
rpttPhpa nkd;fpw ,urj;ij> Kiwg;gb kUe;jhf;fpf; nfhLf;f> mJ fz;Neha;> 
fpue;jp> vz;tiff;Fd;kk;> #iy> ngUk;Gz;> njhONeha;> tspf;FiwT 
Kjypa Neha;fis ePf;Fk; vd;g. 
ew;Fzk; 
1. FUjpiar; Rj;jp nra;J JHePiu ePf;fy; 
2. FUjpiaAk; Rf;fpyj;ijAk; ngUf;fy; 
3. grpiaj; J}z;ly; 
4. fpUkpfisf; nfhd;W Gz; Giufis Mw;wy;. 
5. cly; KOtijNah my;yJ cs;Sk; GwKkhd cWg;gpd; gFjpiaNah> 
cWg;gpd; KOtijNah gw;wp tpahjpfisf; Fzkhf;fy; 
6. Kf trPfuj;ij cz;L gz;zy; 
7. kwjpia xopj;J %isf;F ftd rf;jpiaj; juy;. 
8. euk;Gf; fl;lq;fis td;ikAwr; nra;jy; 
9. kdj;ij xU epiyapy; epWj;jp Qhdj;ij tpUj;jp nra;jy; 
10. %g;ig xopj;J MAis tsh;j;jy;. 
jPf;Fzk; 
 ,urj;ijr; rhpahd Kiwapy; Kbj;J cz;zhjjhy; tUk; Fw;wq;fs; 
mNefk; vd;Dk; fUj;ij Njiuah; $wpAs;shH. 
 kdpjd; nra;Ak; gQ;rkh ghjfq;fis tpl> ,urj;ijr; rhpahd Kiwapy; 
Rj;jp nra;J. gw;g nre;J}uq;fsha; Kbf;fhJ nfhlg;gJ kfh ghjfkhFk;.  
mt;thW cgNahfpf;Fk; kUj;Jtd; kdpjth;f;fj;jpDs; Nrh;f;fj; jf;ftdy;yd;> 
mtNd nfhb ,akd; Mthd;. 
 Rj;jp nra;ahj ,urj;ij cgNahfpg;gjhy; cly; Kw;Wk; nte;J 
Nghtjd;wpg; gw;fnsy;yhk; fod;W Ngha;tpLk;. 
,ur Rj;jh Rj;jFzk; 
 Rj;jp nra;ag;gl;l ,urk;> kuzj;ijg; Nghf;Fk; mkph;jk; Nghd;wJ. 
 Rj;jp nra;ag;glhj ,urk;> kuzj;ij cz;lhf;Fk; tplk; Nghd;wJ. 
ghjurj;jpd; gj;jpak; 
 “kw;rKg;G rPNjh\;z ke;jhjp tj;njz;nza;  
 Jw;rkj;jp aq;ifg;G J}TGsp –iar;rw;Wq; 
 $l;lhkw; #jq; nfhLg;gUz;lh iur;rkd;ghw; 
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 fhl;lhkw; whkpUj;jf; fhz;”. 
,ur rk;ge;jkhd kUe;Jfs; mUe;Jq;fhyj;J kPd;> cg;G> kpFrPjk;> kpF cl;lzk;> 
ke;jg;nghUs;> vz;nza;> kJghdk; ifg;G> fhHg;G> Gspg;G RitAs;s nghUs;fs;> 
ngz;Nghfk; Mfh. 
,urk; eQ;R FwpFzk;: 
 Fw;wk; cz;lhf;f $baJ- J}a;ik nra;ahjJ> ed;whf Kbf;fg;ngwhjJk;> 
msTf;F mjpfkhdJk;. 
thapy; mr;ruj;ijg; Nghy; Gz;> gdq;fs;isg;Nghy; tha; Fok;Gk;> gw;re;Jfspy; 
<W fl;;Lk;> thapy; ePu; ngUFk;> njhz;ilnte;J Gz;> fhJ nrtpLgly;> tapw;wpd; 
kPJ gl;ilg;gl;ilahfj; Njky;> Nghfq;nfly;> fz; ghu;it ,oj;jy;> nrk;gil 
Nghy fhzy;> fhybfspy; ntbg;G. NkYk; gpj;jd; Nghd;W tha; gpjw;Wk;> 
Jzpfis mtpo;j;J vupAk;> tpau;it ngUFk;> jz;zPupy; Kq;fp ntsptUk; 
Mfpa FwpFzq;fisf; fhl;Lk;. 
,ur eQ;R KwpT: 
 nts;is Kl;rq;fd; ,iyr; rhW my;yJ kpjpg;ghfy; ,iyr; rhW (80 
kp.yp) fhiyAk; khiyAkhf 3 ehs; nfhLf;fTk;. 
 
ypq;fk;: 
nghJFzk; 
 “Ngjp RuQ; re;ep ngUtpuz ePnuhLj 
 fhjfb fhrq; fug;ghd;Gz; - Nzhj 
 TUtpypq;f rq;fjkh A+Wfl;b Ak;Nghq; 
 FUtpypq;f rq;fkj;ijf; nfhs;”. 
 “Mjp apujTUf; fhjyhw; rhjpypq;f 
 Nkhjp ypujFz Kw;Wlypw; - wPJGhp 
 Fl;lq; fpue;jp nfhLQ;#iy thjKj 
 Yl;lq;F Neha;fisNahl; Lk;.” 
nghUs;: Njhw;wj;jpy; ghjur cUf;fhfpa rpte;j epwj;ijAila rhjpypq;fKk;> 
mJ Nrh;e;j kw;iwa kUe;JfSk;> me;j ,ur Fzj;ijf; nfhz;L Jd;gj;ij 
cz;Lgz;Zfpd;w Ngjp> Ruk;> re;epghjk;> jPuhg;Gz;fs;> 
mjp%j;jpuk;>fhzhf;fbtplk;> fhrk;> fug;ghd;> rpuq;F> nrhy;tjw;Fk; ghHg;gjw;Fk;> 
ntWg;Gj; Njhd;Wk; guT Ezhf;fha;f; fpue;jp> Fl;lk;> fpue;jp> nfhLik nra;fpd;w 
#iy> thjNeha; KjypaitfisAk; kw;Wk; clypy; kiwe;J ,Uf;Fk; 
gpzpfisAk; ePf;Fk; vd mwpf. 
epyj;njOe;j gpzp-gpUjptp G+j cWg;Gfspy; cz;lhk; Neha;fs; ryg;gpzp 
– mg;G G+j cWg;Gfspy; cz;lhk; Neha;fs;. 
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 kw;Wk; ruf;FfSf;nfy;yhk; ,ypq;fk; ,iwnadTk;> Nkf Neha;fSf;F 
ekd;Nghd;w njdTk; $wpAs;sdH. 
msT 
 ,jidg; gj;J cSe;njil (650 kpfp) tiu cs;Sf;Fk;> miu 
tuhfndil (2.1 fpuhk;) Gif NghLtjw;Fk; cgNahfpf;fyhnkd;W ig\[ fy;gk; 
$Wfpd;wJ. 
,ypq;f eQ;Rf; FwpFzk; 
 thab> cz;zhf;F> Fus;tis> ngUq;Fly; Kjypad nte;J 
gRk;Gz;zhfpg; gUj;jpg;G+itf; frf;fp> ntapypy; ,l;lhw;NghypUf;Fk;.  thapy; 
fhuk; glKbahJ.  czT> ePH Kjypad mUe;Jtjw;Fk;> NgRtjw;Fk;> 
tUj;jj;ijf; nfhLf;Fk;.  thapy; nfl;l ehw;wk; tPrp> Ritnfl;L> tapw;wpy; 
vhpr;riyAk; cz;L gz;Zk;.  ckpo;ePH nfl;lgdq;fs;isg; NghyTk;> fhbj; 
jz;zPiug; NghyTk; ntz;ikahfTk;> Fok;ghfTk; fhzg;gLk;. 
 
 
G+uk; (,urf; fw;G+uk;) 
nghJFzk;  
 “,ilthj #iy nahp#iy Fd;ke; 
 njhilthio thjkhQ; Nrhzp apilahNjh 
 nthf;Fur fh;g;G+u nkhd;Nw asnthLey; 
 ,f;Fnty;yj; NjOeh sP.” 
ey;y ,ur fh;g;G+uj;ij msTld; fUk;G nty;yj;jpy; VOehs; nfhLf;f> ,Lg;igg; 
gw;wpa #iy> Mq;fhq;F vhpr;riyj; jUfpd;w #iy> thj Fd;kk;> njhilthio> 
thjuj;j Neha; Kjypad jPUk;. 
 Nkw;$wpa nra;As; rpy Neha;fisNa Fwpg;gpbDk;> G+uj;ij Ruk;> kQ;rl; 
fhkhiy> gpj;j Njhlk;> rPjNgjp> ePHf;Nfhit> tpuzre;jp> Mwhj tpuzq;fs;> Nkf 
tpahjp nrhpahik> the;jp> Ngjp> fpUkpNeha;> fPy;thjk;> nrhwp> rpuq;F> kyge;jk; 
Kjypaitfl;Fk;> jiytyp Nghd;w kw;iwa Neha;fSf;Fk; cgNahfpg;gijg; 
gof;fj;jpy; fhzyhk;. 
G+u eQ;Rf; FwpFzk; 
 G+uk; tplkpj;jhy;> Kfj;jpy; nrt;thg;Gg; Nghy Kfg;gU> NtHFU mjpfkha; 
cz;lhjy;> khHgpd; gs;sj;jpy; gUf;fl;bg; Gz;zpuzk; fhZjy;> ,ijg; 
gf;fj;jpy; typ> thapy; fhuk; glhjgb Gz;zhjy;> gPrtPf;fk;> cz;zhf;fpy; 
tpuzk;> Ngjp> ,uj;jf;fopr;ry; Kjypa JHf; Fzq;fisf; fhz;gpf;Fk;. 
 ,J tpiuthf ePhpy; fiuahJ.  ,J mjpf mstpy; clk;gpw;Fs; nrd;why; 
eQ;Rj; jd;ikiaf; fhl;Lk;.  mitahtd gy;yPWfSk;> ehTk;> thAk;> ce;jpAk;> 
jhilapd; cl;gf;fKk; Gz;zhFk;.  tha; jpwf;f KbahJ.  ehtpy; ePH Ruf;Fk;.  
me;ePhpy; xU tifahd ehw;wk; tPRk;. mijAk; tpOq;f KbahJ. 
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eQ;R KwpT 
 “gfUtha; G+uj;ijg; ghq;Fld;wpd; NwhHfl; 
 fpfyhpa Fy;iyapidrhwPf – jfTila 
 Vuz;l nea;ah nkopyThp NtuhFk; 
 rPHnfhz;l ghfypiy NjH” 
1. Jsrpr;rhW (m) rpw;whkzf;F nea; (m) ghfy; ,iyr;rhW 
Mfpaitfspy; xd;iwf; nfhLf;f Kiwg;gb 3 (m) 5 ehs; (m) eQ;R 
jPUk;tiu nfhLf;fNtz;Lk;. 
2. mThp Nth;g;gl;ilia nte;ePH tpl;liuj;J xU Ntisf;Fr; Rz;ilf;fha; 
msT tPjk; fhiyapYk; khiyapYkhf eQ;R jPUk; tiuf; nfhLj;J 
tu Ntz;Lk;. 
3. epyg;gdq;fpoq;Ff; FbePH :  epyg;gdq;fpoq;F> ty;yhiu Nth;> 
nghd;dhq;fhzp Nth;> jz;Lguq;fp ,tw;iw tiff;F 10 fpuhk; vLj;J 
rpijj;J mjpy; 650kpyp ePH tpl;L vl;Lf;nfhd;whff; FbePH nra;J 
fhiy> khiy ,uz;L (m) %d;W thuk; nfhLj;J tu G+uj;jpd; tPW 
jzpAk;.   (Fzghlk;) 
tPuk; (rt;tPuk;) 
nghJFzk; 
 “Fd;knkhL Fl;lq; nfhbatdp yj;jpul;L 
 Jd;khq; fprg;ngUf;fQ; #iyNeha; - td;ikAW 
 fhkpag;Gz; zhjpaNeha; fz;lhw;rt; 
 tPundDQ; rhkpeh kj;ijAr; rhp”. 
rt;tPuj;jpd; ehkj;ij cr;rhpj;jhNy Fd;kk;>FiwNeha;> jPq;if tpistpf;fpd;w 
kfh thjNuhfq;fspd; $l;lk;> JHkhkpr tsh;r;rp> #iyNeha;fs;> 
td;iknghUe;jpa ngz; Nghfj;jpdhy; tpisfpd;w (nfhWf;F> miuahg;G> 
Kjypa) Gz;fs; Mfpa ,it ePq;Fk;. 
 ,jidg; gytifg;gl;l fz;Nzha;fSf;Fk; cgNahfpf;fpd;wdh;.  
rt;tPuj;jpd; msT 
 ,jid 1/32 cSe;njil (2 kp.fpuhk;) apypUe;J 1/16 cSe;njil (4 
kp.fpuhk;) tiu cgNahfpf;fyhk;.  Nkw;gbd; eQ;rhk;. 
eQ;Rf;FwpFzk; 
 ,J ePhpy; Ntfkhff; fiuAk; jd;ikAilaJ.  ,J cl;nfhz;lTlNdNa 
FUjpNahL fye;J tplj;ij kpf Ntfkhf tpistpj;JtpLk;.  ,J 
gpwiuf;nfhy;Yk; nghUl;Lk; jw;nfhiy Ghpe;J nfhs;sTk; gad;gLj;JtJz;L. 
 ,ij cl;nfhz;lhy; thapy; xUtiff; fspk;Gr;Rit cz;lhFk;.  thapy; 
ePUWk;.  tha; Gz;zhfp tPq;Fk;.  njhz;ilAk; Mkhrak; ahTk; tPq;fpg; 
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Gz;zhFk;> the;jpAk; kyNgjpAk;> FUjpf; fopr;rYk; cz;lhFk;. vr;rpiyf;$l 
tpOq;f Kbahjgb njhz;ilapy; typ Vw;gLk;.  Kfk; tPq;fptpLk;> clk;gpYs;s 
Njhy; KOtJk; gl;il gl;ilahf ntbj;Jr; rPiy ePH tbAk;> gf;fk;> tpyh 
Kjypa ,lq;fspy; mjpf NehTk;> Filr;rYKz;lhFk;> mjpfePH Ntl;if> 
tpf;fy;> %Hr;ir> kaf;fk;> typ Kjypad cz;lhFk;.  ,NjhL rhTk; cz;lhFk;. 
eQ;R KwpT 
 Kiwahfr; rt;tPu nkha;Foyha; nfhz;lhy; 
 rpWneUQ;rpw; rhWz;zj; jPUk; - miwaf;Nfs; 
 ePypNt uhFNk nea;r;rl;br; rhwhNk 
 ghyp njd;dq; fs;Sk; gfh;. 
nghUs; 
 rpW neUQ;rpw;rhW> ePypNth;g;gl;ilf; fy;fk;> nea;r;rl;bf; fPiur;rhW> 
njd;dq;fs; ,itfspnyhd;iw eQ;rpd;td;ikf;Fj; jf;fmstpy; eQ;R 
KhpAkl;Lk; nfhLf;f Ntz;Lnkd;gjhk;. 
NfhopKl;il ntz;fUitj; jz;zPH my;yJ ghYld; fye;J mbf;fb 
nfhLj;J te;jhYk;> ,sePH> mUe;jpdhYk; tPuj;jpd; eQ;R ePq;Fnkd;g.  ,jid> 
 “mz;lj;jpd; ntz;fUit ahtpd;gh ypw;fye; 
 Jz;Ltu tPuD DukfYq; - fz;lhptha; 
 Vzw;nfhbNa apseP uUe;jpLD 
 khzg;ngUik tOj;J. 
vd;w fUT+uhH jz;lfr; nra;Ashy; czh;f. 
 
Plants are the best natural source of medicine the world. According to Food and 
Agriculture Organisation (FAO) reported that on an average 70-80% of people in the 
world encroaches herbal medicines to prevent and cure diseases. And it is estimated 
that about 25% of synthesized drugs are from medicinal plants.  
Tribulus terrestris: 
Pharmacological actions: 
“ey;y neUQ;rpyJ ehSq;fp upr;rhuj;ij 
ty;y Rukdiy khw;Wq;fhz;-nky;ypaNy! 
khepyj;jpy; fy;yilg;Gk; thq;fhj ePHfl;Lk; 
$DWnka; thjKk; Nghf;Fk;. 
Nkfntl;il ePHRWf;F tPWjpup Njhlk;Gz; 
NtfhRu jhfntg;gk; tpl;nlhopAk;-Nghfe; 
jUQ;rpd kjiynkhopj; ijaNy! ey;y 
neUQ;rp yjid epid.” 
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 Nourishing, its medicinal property pacifies vata dosha, increases BMR, relieves 
spasmodic pain and cures bladder ailments such as oliguria, burning micturition, anuria 
and leucorrhoea.  
Recent studies endorsed that it has specific activities in improving sexual 
function(aphrodisiac), cardiac protection and also has anti-urolithic, anti-diabetic, anti-
inflammatory, anti-tumour, anti-spasmodic and anti-oxidant activities to enhance 
health. In Tribulus terrestris, there are 108 kinds of steroidal saponins were identified 
in experiments. The major phytoconstituents responsible for the medicinal uses are 
kaempherol- glucoside, Terrestrin (C, D, E) - saponin, Tribulusterine and vanillin- 
Alkaloids and Furostanol- glycoside (46). 
In experience, the ash form of whole plant is claimed to be effective in treating 
Rheumatoid arthritis. The whole plant used in the treatment of male infertility and 
induces spermatogenesis.By highlighting the anti-oxidant property, a research reported 
that it reduces the oxidative stress and free radicals formation induced by mercuric 
chloride treatment.(47)(48) 
Moringa oleifera: 
Pharmacological actions: 
“tpopFspUk; gpj;jk;Nghk; tPwUrp NaFk; 
 moptpe; JTk;G\;b ahFk;-vopyhH 
 xUq;ifaf yhffw; Gilth zifNa  
 KUq;ifapd; g+it nkhop.”  
The pharmacological activities studied in Moringa oleifera were 
antiproliferation, hepatoprotective, anti-inflammatory, anti-nociceptive, anti-
atherosclerotic, oxidative DNA damage protective, anti-peroxidative and 
cardioprotective. 
 Especially siddha literature describes that M.oleifera flower can be used as 
emmenagogue and it also induces spermatogenesis with increased secretion of semen 
from seminal vesicle. 
Several studies reported that it is effective in treating infections, enlarged spleen, 
neuronal disorders, fever, cough, ulcers, dyspepsia and dysmenorrhoea. The major 
phytochemical pterygospermine is the antibiotic principle against gram positive, 
negative and acid fast bacteria.(49) Recent researchshows that it can reduces 
peroxidative reaction in the testicular membrane and increases healthy spermatozoa 
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production.(50) It is reported that M.oleifera reduces testicular toxicity induced by 
mercuric chloride.(40)(48) 
 
Mother’s milk: 
Human breast milk is uniquely superior for infant feeding in the period of ‘crucial 
window’ age. Majorly it contains an average of 1.1% protein, 4.2% fat, 7.0% 
carbohydrate and 72 kcal of energy per 100g of milk.(51) It is documented that feeding 
milk decreases infectious diseases (bacterial meningitis, bacteraemia, diarrhoea, 
respiratory tract infection, otitis media and sepsis).  It contains vitamin C and E, 
superoxide dismutase, catalase and glutathione peroxidase and thus proves that it has 
antioxidant properties.(52) Apart from this, it enhances the immune mediated 
mechanisms and maintains the texture of tissues in human. Antioxidants are considered 
to be the supreme power to avoid cell damage and DNA damage. A protein lactoferrin 
(iron-binding transferrin protein) which is abundantly present in breast milkbinds to 
iron which attenuates the conversion of free radicals.Abundant antioxidants were 
present in human breast milk. But the antioxidants level decline day by day, if it is 
refrigerated. Another study reported that there is a marked increase of an oxidative 
stress marker malondialdehyde in refrigerated milk and not in frozen milk samples. But 
there is a decreased glutathione peroxidase activity in both refrigerated and frozen milk 
samples.  
jd;dpankd; Nwhjpr; rUtNjh \q;fs;Nghk; 
cd;dpa jhg nkhopAq;fhz;-re;epnahL 
thjRuk; gpj;jRuk; td;fgr;Rue;jdpAq; 
Nfhjpy;td; ikAz;lhq; $W. 
 
Honey: 
Honey is the worldwide recognised nutritive sweetest liquid for human wellbeing. 
Since ancient Egyptians, Greeks, Romans and Chinese has been used traditionally used 
in medicinal field to treat gastric ulcers, sore throat, cough and ear aches. (53) On 
external application, the therapeutic effect heals the wound fast, cleans and clears the 
infectious tissues and reduces inflammation. Naturally it composed of 82.4% 
carbohydrates, 38.5% fructose, 0.5% protein, 31% glucose and 17.1% water. 
In Siddha system of medicine, it can be used as demulcent, laxative, antiseptic agent, 
expectorant, astringent, best appetizer, general tonic and hypnotic. Especially in 
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children it act as diuretic and relieves indigestion. Not only as internal adjuvant, plays 
a potential role in healing wounds externally. Though this this system elaborates the 
purification method of honey for its adjuvant use in the treatment period. In ancient 
period, Egyptians and Asians used honey to delay the action of decomposition in dead 
bodies. The same events evidenced among Greek population. Eventually in this system, 
it plays a vital role as adjuvant in enhancing the efficacy of the therapeutic dose of 
medicine. Some of the literatures documented the importance of honey as adjuvant are 
given below: 
“mDghdj; jhNy atpo;jk; gypf;Fk; 
,dpjhd Rf;F d;dypQ;rp-gpDKjfq; 
Nfhkak; ghy;Kiyg;ghy; Nfhnea;Njd; ntw;wpiyePH 
Mkpijah uha;e;Jnra yhk;.” 
“mDghd kha;g;gpd; mtpo;jKkha;j; Njhd;wp 
fdkhd Njfepiy fhl;bg;-gpDNk 
aurd; Kjy;Nth iuAkhl;L tpj;jhNy 
gpurj; jpdhw;Nghk;.” 
Njud; nghUs;gz;G Ehy;. 
  
 
Background: 
Preparation and standardization always play a trivial role in pharmacological 
understanding of any traditional drug formulation. This becomes more complicated if 
the final drug authentication procedures of the particular drug formulation are not very 
well known. Few Siddha scholars of present time have attempted to establish standards 
for commonly used Siddha formulations, such as Amukkarā cūrṇam (54) Kānta 
centūram(55) Liṅka centūram No. 1(56) Psoriatic Care 777 oil (57), Mattaṉ tailam(58) 
and. Tāḷakakaruppu(59) etc. However, most of the works fail to address the exact need 
for standardization. Several Pāṭāṇam (arsenic based formulations) of Siddha system 
are currently researched for its clinical efficacy in Malignancies.(60)(61)(62)(63). In 
those works, the standard range has been fixed by preparing the formulation at least for 
three times. As far as the herbo-metallic siddha drugs (HMPs) are concerned, traditional 
authentication procedures are well established only for paṟpam and centūram. Though 
no general authentication procedures are known for accessing the quality of meḻuku 
based HMPs in classical Siddha texts, few vaittiyarkaḷ in Kanniyakumari district assert 
the completion of meḻuku type of HMPs by rubbing them in skin and placing them in 
direct sunlight. If any glittering particles are seen or if any skin irritation is observed, 
the drug is deemed to be incomplete and the entire process has to be repeated again. 
Absence of the above mentioned signs ascertain that the drug preparation is complete. 
As our trial drug Panca Cuta Meluku (PCM), has 5 inorganic and three organic 
ingredients, the preparation and standardization should be performed with at most care 
to avoid any errors. This chapter primarily deals with the preparation process and 
standardization process espoused in present work. 
Materials and Methods: 
The preparation of any HMPs consists of following standard procedures: 
1. Collection of raw materials 
2. Authentication of the raw materials 
3. Purification of raw materials 
4. Preparation of drug 
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5. Final authentication of drug 
The same process was followed in this work.  
Collection of Raw Materials: 
 The raw drugs Iracam, Liṅkam, Pūram, Vīram and Iraca centūram were 
procured from local store in Nagercoil, Kaniyakumari District. The Mercury (Batch no: 
089805) was purchased from Spectrum Reagents and Chemicals pvt.ltd.Neruñcil 
camūlamand Muruṅkaipū were collected from regions around Tuckerammalpuram, 
Tirunelveli. Mother’s milk were generously donated by lactating mother’s hospitalized 
in various private hospitals in and around Palayamkottai, Tirunelveli, Tamil Nadu, 
India. Honey was purchased from outlet of Khadhi Kraft, Gandhigram Lakshmi 
SevaSangam (LSS).  
Authentication of raw materials 
 The raw materialsIracam, Liṅkam, Pūram, Vīram and Iraca centūram were 
authenticated by experts at Department of Chemistry, Central Council for Research in 
Siddha, Chennai. Tribulus terrestris (Neruñcil camūlam) [Voucher Specimen No: 
T170619006T] & Moringa oleifera (Muruṅkaipū) [Voucher Specimen No: 
M170619005O] were authenticated by experts at Siddha Medicinal Plants Unit, (Under 
CCRS), Mettur, Tamilnadu.   
Purification 
 The purification protocol was performed as per the descriptions in classical 
Siddha text.(25) 
 Iracam was purified by filtering in a white cloth for 1000 times.  
 Liṅkam and Iraca centūram were purified by soaking in lemon juice and 
mother’s milk for a period of one day each.  
 A mixture of black betel leaves and black pepper (10 grams each) ground with 
sufficient quantity of water and dissolved in 2L of water was placed insidean 
earthen pot. Pūramwas tied in a cotton cloth and was suspended inside an 
earthen pot by tying on a stick placed on neck of the earthen pot in such a way 
that it gets immersed inside the liquid. Then the earthen pot was heated till the 
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liquid in pot was reduced to one-fourth. The left over material was washed and 
dried. 
 
Figure 3. 1: Image of traditional set up of purification process of Pūram 
 A mixture of 10 grams of camphor dissolved in 2 L of tender coconut was placed 
inside the earthen pot andvīramwas tied in a cotton cloth and was suspended 
inside the earthen pot by tying on a stick placed on neck of the earthen pot in 
such a way that vīram doesn’t get immersed inside the liquid.  
 Tribulus terrestris was purified by removing the dried, pale leaves and washed 
in running water. 
 Moringaoleifera was purified by removing the stalks, dried flowers, polygons 
and qurcones and washed in running water. 
 Mother’s milk was purified by heating in a silver vessel followed by filtration. 
 34 Preparation and standardisation 
 
 
Figure 3. 2: Image of traditional set up of purification process of vīram 
 
Preparation of medicine: 
The protocol espoused in preparation of PCM is described in Figure.3.3. The PCM is 
prepared by traditional Siddha method call as curukku kuṭuttal. Briefly, all the metallic 
ingredients were ground into fine powder as per the order mentioned in 
Figure.3.3followed by heat treatment in an earthen pan placed over a stove. Afluid 
containing equal mixtures of juices extracted from Moringa oleifera, Tribulus terrestris 
and mother’s milk is added in drops in such a way that the sample in earthen pan doesn’t 
become dry. The temperature is maintained between 250-300oC (kamalākkiṉi).The 
process is continued till all the juices are utilized. 
Note: The whole preparatory process should be performed under the shade of a Tamarind tree. The 
persons engaged in preparation should consume only milk and rice during the day of preparation. Head 
cap, face mask and gloves should be worn all through the process. 
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Figure 3. 3: Schematic representation of preparation protocol of PCM 
PLIM Parameters: 
Various analytical specifications were performed as per the Pharmacopoeial laboratory 
of Indian Medicine guidelines and the reference followed for analysis is tabulated 
below.  
Table 3. 1: Methods followed for PLIM parameters analysis 
S No 
Parameters Reference of test methods 
1 Appearance IP Vol-I, 1996, p7 
2 Total solids IP Vol-I, 2014, p277 
3 Total Ash IP Vol-I, 2014, p98 
4 Acid insoluble ash IP Vol-I, 2014, p98 
5 Loss on Drying at 105°C IP Vol-I, 2014, p162 
6 Carbohydrates Biochemical Methods, Sadasivam.S,2005,p8-9 
Qualitative analysis: 
Presences of various contents in PCM are determined using following methods. 
Test for calcium - 2ml of the above prepared extract is taken in a clean test tube. To 
this add 2ml of 4% ammonium oxalate solution. 
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Test for sulphate - 2ml of the extract is added to 5% barium chloride solution. 
Test for chloride - The extract is treated with silver nitrate solution. 
Test for carbonate - The substance is treated with concentrated HCl. 
Test for starch - The extract is added with weak iodine solution. 
Test for ferric iron - The extract is acidified with glacial acetic acid and potassium 
ferro cyanide. 
Test for ferrous iron - The extract is treated with concentrated nitric acid and 
ammonium thiocyanate solution. 
Test for phosphate - The extract is treated with ammonium molybdate and 
concentrated nitric acid. 
Test for albumin - The extract is treated with esbach’s reagent. 
Test for tannic acid - This extract is treated with ferric chloride. 
Test for unsaturation - Potassium permanganate solution is added to the extract. 
Test for the reducing sugar - 5ml of benedict’s qualitative solution is taken in a test 
tube and allowed to boil for 2 minutes and add 8-10 drops of the extract and again boil 
it for 2 minutes. 
Test for amino acid - One or two drops of the extract is placed on a filter paper and 
dried well. After drying 1% ninhydrin is sprayed over the same and dried it well. 
Test for zinc - The extract is treated with potassium ferro cyanide. 
Characterisation: 
TGA (Thermo-gravimetric analysis) was performed by placing 2-5 mg of sample in an 
alumina cup and heated at the rate of 10°C/min up to 1000°C in a nitrogen atmosphere 
with a flow rate of 100 ml/min using an SDT Q600 (TA Instruments, USA).  
FTIR (Fourier transform infra-red) spectra of samples were recorded between 4000 and 
400 cm−1 in the IR spectrometer (Spectrum 100, Perkin Elmer, USA) using KBr pellet 
method.  
The elemental composition of the samples was determined using XRF (X-ray 
fluorescence) spectrometer (S8 Tiger, Bruker AXS, Germany) using a 4 kW Rhodium 
anode X-ray tube by using boric acid pellet method.  
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The crystallinity of the samples were analyzed using an X-Ray diffractometer (D8 
Focus, Bruker, Germany), by irradiating with Cu-kα radiation. The analysis was 
performed from 10oto 60 o(2θ) with a step size of 0.01 o. 
Note: As the samples of  PCM-final was in waxy consistency, 25 g of PCM-FINAL is heated for 15 
minutes at temperature between 250-300ºC and the remaining left over sample (2.78g) is given for XRD 
analysis. PCM-BT was given as such for XRD analysis. 
Results: 
The difference in weight of the raw material before and after purificationis shown in 
table 3.2. 
Table 3. 2: Difference in weight after purification of raw materials 
Drug Weight (g) Observations 
Before 
purification 
After 
purification 
Iracam 100 95  At the end of each time, it is noted that there 
is a presence of blackish powder  
Pūram 100 80.9  No notable changes were observed 
Vīram 100 95.3 No notable changes were observed 
Liṅkam 100  98.7 No notable changes were observed 
Iracacentūram 100  97.5 No notable changes were observed 
Preparation: 
50gof Iracam, Liṅkam, Pūram, Vīram and Iraca centūram are subjected to heat with 
275 ml of Neruñcil camūlam juice,Muruṅkaipū juice and Tāypāl and 280g of final drug 
was obtained. 
Standardization: 
Primary chemical analysis of PCM showed the presence of calcium, sulphate, chloride, 
ferrous form of iron, unsaturated compounds, reducing sugar and amino acid. Few 
substances such as carbonate, starch, ferric form of iron, phosphate, albumin, tannic 
acid and zincare absent in PCM. The results of PLIM standards is shown in table 3.3 
Table 3. 3: Results of PLIM standards for PCM 
S No 
Parameters Results 
1 Appearance Black coloured wax 
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2 Total solids 10.68%w/w 
3 Total Ash 5.678%w/w 
4 Acid insoluble ash 0.9728%w/w 
5 Loss on Drying at 105°C 4.770%w/w 
6 Carbohydrates 4.825.%w/w 
TGA analysis: 
The two different methods (rise of temperature at 10oC / min and 20oC/ min) of TGA 
analysis of PCM is shown in figure 3.4. This shows that maximum degradation of the 
substances in PCM happen around 450oC. 
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Figure 3. 4: TGA analysis of PCM 
IR spectroscopy: 
IR spectra of PCM-BT, PCM – Final and AT is shown in figure. 3.5. Peaks at 474 cm-
1 and 1614 cm-1 in IR spectra of PCM-BT were assigned to the stretching vibrations of 
HgCl2 and Si-C4linear vibrations respectively. The peaks at 3526 cm
-1 and 3585cm-1 
were due to the OH stretch. Peaks at 1629 cm-1, 2896 cm-1 and 2855 cm-1 in AT shows 
the presence of symmetrical carbonyl stretching and bending. Peaks at 1038 and 1078 
could be due to in plane bending of C-H bond.  The peaks at 3007 and 3389 show the 
OH vibrations. 
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Figure 3. 5: IR spectra of PCM- Final, AT and PCM-BT 
The peaks at 1746 cm-1, 2048 cm-1, 2061cm-1 and 2129 cm-1 could plausibly due to the 
overtones produced by vibrations of carbonyl bonds. PCM-Final showed peaks 
corresponding to Hg-S stretch of Cinnabar at 589 cm-1 and 1121 cm-1(64). Peaks 
corresponding to Hg-Cl stretch of HgCl2 is noted at 464 cm
-1 and 723 cm-1.  A shift of 
9 cm and 6 cm is observed in 1168 cm-1 and 1378 cm-1 peaks. 
X-Ray Fluorescence spectroscopy (XRF): 
Table 3. 4: Elemental composition and oxidation state of PCM analysed using XRF 
Oxide form of PCM-BT Elemental form of PCM-FINAL Oxide Form of PCM-
FINAL 
Formula Concentration 
(%) 
Formula Concentration (%) Formula Concentration 
(%) 
Hg  87.5 Hg 39.2 SO3 31.6 
PbO 2.5 S 17.4 Hg 27.0 
Cl 1.3 Cl 14.3 Cl 10.3 
SiO2 0.6 K 10.3 K2O  9.1 
MnO 0.2 Ca 6.0 SiO2 6.0 
Others 7.9 Si 1.7 CaO 5.9 
 P 1.7 P2O5 2.5 
Mg 1.6 MgO 2.3 
Others 7.8 Others 5.2 
The elemental composition of PCM-BT and PCM-FINAL analysed using XRF is 
tabulated in table.3.4. 
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X-Ray Diffraction spectroscopy: 
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Figure 3. 6: XRD spectra of PCM-BT and PCM-final 
XRD spectra of PCM-BT, PCM-Final and AT are shown in Figure 3.6. PCM-BT shows 
significant peaks at 31.46 2θ, 26.77 2θ, 28.43 2θ, 43.92 2θ, 20.64 2θ, 54.86 2θ, 52.98 2θ, 
52.01 2θ and 46.04 2θ. Among this, peaks at 20.649 2θ, 21.647 2θ, 28.438 2θ and 30.118 
2θ were assigned to the diffraction of Hg-Clbonds in HgCl2(65). Peaks at 28.43 2θ, 
21.67 2θ, 33.32 2θ, 43.92 2θ and 46.24 2θ were assigned to Hg2Cl2(66).  Peaks at 26.77 
2θ, 31.46 2θ, 43.92 2θ and 46.04 2θ were assigned to HgS vibrations(64). Peaks at 52.015 
2θ, 52.98 2θ and 54.86 2θ could not be assigned to any of the compounds but it 
represents the crystalline nature of the sample. PCM-Final shows significant peaks at 
31.41 2θ, 26.65 2θ, 43.87 2θ, 28.6 2θ, 51.94 2θ, 45.97 2θ, 40.81 2θ, 52.89 2θ, 54.79 2θ 
and 30.73 2θ. Among this, peaks at 31.41 2θ, 26.65 2θ, 43.87 2θ and 45.97 2θ were 
assigned to the HgS diffraction(64). Peaks at 52.89 2θ and 54.79 2θ could not be 
assigned to any of the compounds but it represents the high crystalline nature of the 
sample. 
Discussion: 
The major perspective of this work is to prepare and characterise the PCM by 
employing contemporary methods without losing the traditional essence. After getting 
authentication of raw materials fromChemistry and Plants unit department under 
Central Council for Research in Siddha, the drugs were purified as per literature and 
PCM was successfully prepared. Following preparation, thePharmacopoeial standards 
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were fixed as per the PLIM guidelines. Preliminary qualitative analysis of PCM-final 
showed the presence of   presence of calcium, sulphate, chloride, ferrous form of iron, 
unsaturated compounds, reducing sugar and amino acid and absence of carbonate, 
starch, ferric form of iron, phosphate, albumin, tannic acid and zinc. As the IR spectra 
of PCM-final showed the presence of hydrocarbon peaks, the presence of organic 
substances is confirmed. Hence, TGA was performed to evaluate the amount of organic 
and inorganic substances present in PCM-final. But quantity of organic substances 
could not be evaluated as most of the salts of mercury has melting point less than 400oC 
(67)(68)(69)(70)(71)and the weight loss was approximately 95% at 1000oC.  This was 
quite surprising as the PCM-BT was heated at kamalagni (approximately 250-350oC), 
and we could see an average of 50% decrease in mercury during the preparation that 
lasted for more than 3 hours. However, the weight loss during TGA analysis at 
400oCwas 5-10% depending on the rate of rise in temperature.  This implies that the 
mixture of juices and mother’s milk would have played a crucial role in prevention of 
evaporation of mercury. Albeit, this can be confirmed only after performing various 
control experiments. As the percentage of organic could not be established, XRF was 
performed to understand the elemental nature of PCM-Final.  The presence of 
significant quantity of K, Ca, PCM-BT apart from Hg and Pb that was present before 
curukkukuṭuttal implies that K and Ca would have either come from the mixture of 
juices along with mother’s milk or from Aṇṭatailam. Moreover, shift of hydrocarbon 
peaks to 6-9 cm-1 in IR data denotes the presence of organometallic complex in PCM – 
final.  
Conclusion: 
From the above discussion following conclusions were drawn. 
1. The PCM was successfully prepared as per the descriptions in the Siddha 
classics. The standardization parameters were established following the PLIM 
guidelines. 
2. Preliminary qualitative analysis showed the presence of calcium, sulfate, 
chloride, ferrous form of iron, unsaturated compounds, reducing sugar and 
amino acid and absence of carbonate, starch, ferric form of iron, phosphate, 
albumin, tannic acid and zinc 
3. There is no organic content in the PCM in the before trituration.  
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4. Mercury, sulfur, chlorine, potassium, calcium, silicon, phosphorus and 
magnesium were the major elements found in the final PCM. 
5. The sample before trituration predominantly contains HgS and HgCl2. 
6. The final PCM was found to contain notable quantity of organic materials in it 
along with significant quantity of HgS. The presence of HgCl2/Hg2Cl2 is very 
limited in final PCM. 
2 
 
 
In this expeditious century, the drug resistance was the common trend in medical 
system which leads to the innovation of new drugs. In the development of new drugs 
toxicological screening is essential before human consumption. The US Food and Drug 
Administration states that for the development of drug, it is necessary to screen the 
pharmacological activity and toxicity study in animals.  These type of animal toxicity 
studies began in 1920 still in research. In order to evaluate the safety profile of a drug 
toxicity studies were carried. Many literature formulations in Siddha system of 
medicine hold much medicinal value but it is vital to record the safety profile of the 
individual drug. Here the medicine PCM already exists with toxic symptoms and their 
specific antidotes along with general properties. Thus it was concerned to establish the 
toxicological profile by animal experiments as per OECD guidelines. 
Materials and Methods: 
Adult Wistar rats (6-8 weeks) of both sexes procured from the Central Animal 
Facility, SASTRA University were used for this study. The animals were kept at 21±2 
°C with a 12 h light/dark cycle, with free access to standard rat pellet diet and water ad 
libitum. The experimental protocols were performed after obtaining the necessary 
approval (Approval number: CAF/195/S/IAEC/RPP) from the Institutional Animal 
Ethical Committee (IAEC) of SASTRA University. 
Study Plan - Acute Oral Toxicity Study: 
This study was performed in compliance with OECD 425 (Up and down method) 
guidelines(72). The main test consists of a single ordered dose progression in which 
animals are dosed, one at a time, at a minimum of 24-hour intervals. The first animal 
receives a dose a of 175mg/kg and observed at least once during the first 30 minutes 
after dosing, periodically during the first 24 hours (with special attention given during 
the first 4 hours), and daily thereafter, for a total of 14 days, except where they need to 
be removed from the study and humanely sacrificed for animal welfare reasons or are 
found dead.. If the animal survives for 24 hours, the dose for the next animal is 
increased by [a factor of] 3 .2 times the original dose; if it dies, the dose for the next 
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animal is decreased by a similar dose progression. (Note: 3.2 is the default factor 
corresponding to a dose progression of one half log unit). Each animal should be 
observed carefully for up to 24 hours before making a decision on whether and how 
much to dose the next animal. That decision is based on the 24-hour survival pattern of 
all the animals up to that time.Dosing continues depending on the fixed-time interval 
(e.g., 24-hour) outcomes of all the animals up to that time. The testing stops when one 
of the following stopping criteria first is met: 
(a) 3 consecutive animals survive at the upper bound; 
(b) 5 reversals occur in any 6 consecutive animals tested; 
(c) At least 4 animals have followed the first reversal and the specified 
likelihood-ratios exceed the critical value.  
Body weight was measured once in a week and feed consumption was measured daily. 
Animals were sacrificed at day 14 and gross pathology, if any were noted and taken for 
further investigation. 
Study Plan -28-days repeated oral toxicity 
This study was performed in compliance with OECD 407 guidelines(73)and 
dose administration was performed as per the descriptions in table 1.1.Animals were 
totally divided into 7 groups (Normal control, vehicle control, low dose PCM treated, 
medium dose PCM treated, high dose PCM treated, Satellite control satellitehigh dose 
PCM treated) with 10 animals (5male and 5female) in each group. Normal control and 
Satellite control animals were administered only with distilled water. Vehicle control 
animals were administered with vehicle (honey) without any drug. Low, moderate and 
high drug treated groups were administered with different concentrations of PCM 
dispersed in vehicle (honey). The drug/vehicle was administered for a period of 28 days 
orally using oral gavage tube. All the animals were sacrificed after 28 days and required 
biological samples were collected for further analysis. Body weight changes were noted 
in alternate days and feed consumption was noted daily. 
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Table 4. 1: Study plan: 28-days repeated oral toxicity study 
Animal Group 
No. of animals 
(male +female) 
Dose administration 
Control 5+5 Distilled water 
Vehicle control 5+5 Honey 
Low dose 5+5 Therapeutic dose 
Medium dose 5+5 5 x Low dose 
High dose 5+5 10  x  Low dose 
Satellite control* 5+5 Distilled water 
Satellite high dose* 5+5 10  xLow dose 
Dose: 
As the human therapeutic dose of PCM is already established in the Siddha texts 
(100mg/dose for normal adult with 2-3 times a day) (4), considering the weight of a 
normal adult as 60kg, animal equivalent dose was calculated using allometric dose 
translations(74).  
Animal equivalent dose (rat)=Humandose×HumanKm/AnimalKm 
Animal equivalent dose (rat)= 1.538 ×37/6= 9.48mg⁄day 10mg/day 
Considering the drug was administered twice a day, AED is 20mg/ day. 
Animal equivalent therapeutic dose was fixed as low dose. Medium and high dose were 
fixed as 5 times and 10 times that of the low dose (therapeutic dose) respectively. 
Cage side Observations:  
The toxicity signs from activity, Mobility, nature of the Pupil, Piloerection, 
Tremor, Splenomegaly, Diarrhoea, body temperature, and pallor were noted and scored 
accordingly. Overall summation of all the cumulative score was calculated and the 
observed toxicity status was graphed. In Sub acute study period, individual animals 
were observed on every 7th day for any abnormalities and most of the notable changes 
were observed from day1 to day 14. Those changes were assumed with the following 
scorings and cumulative scores were done. 
1. Activity: 
The activity refers to the behaviour of the animal such as restlessness, jumping, 
sluggishness,  paw lifting, aggressiveness, and alertness were considered to be 
abnormal and scored as ‘1’, Whereas normal behaviour were scored as ‘0’.  
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2. Mobility:  
The mobility mean to be whether the animal moves freely (Score = 0) or moves 
by any external stimuli (Score = 1) or immobile (Score = 2) were noted.  
3. The nature of Pupil:  
To assess the state of pupil in moribund animals, scoring were done in order; 
normal- ‘1’, dilated- ‘2’ and constricted- ‘3’. 
4. Piloerection:  
Piloerection observed over the hairs of the body. The absence of piloerection 
were scored as ‘0’ and presence of piloerection is scored as ‘1’.  
5. Tremor: 
Involuntary shaking movement or involuntary muscle contraction and 
relaxation were recorded. Intentional tremor is an important sign seen in animals which 
are intent for moving. Absence of tremor is scored as ‘0’, Tremor occurs during 
intention for walking is considered as mild tremor which is scored as ‘1’, tremor during 
movements(kinetic movement) is noted a moderate tremor represented as score ‘2’, and 
severe tremor (persistent tremor) as‘3’.  
6. Internal organs- palpation: 
 Internal organs were palpated regularly once in 7 days and no palpable changes 
were noted except spleen. The changes of spleen was almost seen on 8th days and 
recovered back within 3 days. The changes were scored with the following: 
Normal spleen (no marked difference) = ‘0’ 
Mild splenomegaly (elevation during respiration) = ‘1’ 
Moderate splenomegaly (mild elevation) = ‘2’ 
Severe splenomegaly (prominentelevation)= ‘3’ 
7. Diarrhoea: 
The condition of diarrhoea was accessed based on its faecal consistency and 
shape of fecal matter present in the cage on the next day morning. The faecal matter in 
definite shape is scored as ‘0’ and ill definite shape (spread in nature) is scored as ‘1’. 
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8. Body temperature: 
Temperature of the individual animal were monitored at the time of moribund. 
Normal body temperature is scored as ‘0’, hypothermia is scored as ‘1’, and 
hyperthermia isscored as ‘2’ 
9. Pallor: 
 The paleness of the skin especially in tail, ear lobes and paws of animals were 
observed.  Absence of paleness is scored ‘0’ and presence of Paleness scored as ‘1’.  
Overall toxicity assessment and scoring system 
 The toxicity signs from activity, Mobility, nature of Pupil, Piloerection, Tremor, 
Splenomegaly, Diarrhoea, body temperature, and pallor were noted and scored 
accordingly. Overall summation of all the cumulative score was calculated and the 
observed toxicity status was graphed.  
Haematology and Biochemical Analysis: 
About 1mL of blood samples were collectedfrom all the animals on 29th day from retro-
orbital plexus before sacrifice.Haematology analysis was performed in whole blood 
using hemocytometer. 
The serum was separated by allowing the remaining blood sample to coagulate at room 
temperature followed by centrifugation at 605rcf for 10 minutes. Biochemical analysis 
was performed in this serum using following methods 
Histopathology Analysis: 
After sacrifice, the specific organs were isolated, washed with cold saline, weighed and 
finally fixed in 10% buffered formalin solution for histopathological studies. The fixed 
tissues were embedded in paraffin and the sections were cut in 3-5μm slices and were 
stained using haematoxylin and eosin. The stained tissues were observed under light 
microscope. The scoring was given to the pathological features seen in the slide as 0 
for normal, 1 for minimal, 2 for mild, 3 for  moderate, and 4 for marked and 5 for 
severe. 
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Isolation of protein and Western blotting: 
Total protein from the collected rat tissues were isolated using 10X cell lysis buffer 
(V8571,Promega, USA) containing protease inhibitor cocktail purchased from Sigma, 
USA (P8340). Briefly, to the cell pellet from 34.8 mm petri dish 30 µL of lysis buffer 
was added. The cell mixture was pipetted out persistently for 30 sec followed by 
centrifuging at 12000 rpm at 4ºC for 5 min. This step was repeated 3 times followed by 
centrifugation at 14000 rpm at 4ºC for 20 min. The resulting supernatant is then stored 
in a fresh vial until further use.  
For western blotting the following steps were followed: 
1. 50µg of protein separated earlier was utilized. This protein lysate was loaded onto 
a 10% sodium dodecyl sulfate (SDS) gel and was ran at 110Voltage (V).  
2. After electrophoresis the protein ran in SDS gel was transferred to an immune-blot 
polyvinylidene-di-fluoride (PVDF) membrane (1620112, Bio-Rad) at 100V for 1 
hour using Trans-Blot Turbo Transfer System (Bio-Rad).  
3. After transfer of protein the blot was incubated for 1 hour with 5% BSA prepared 
in 1X tris buffer saline-tween 20 (TBST) buffer on a gel rocker for blocking the 
surface from cross liking of antibody with the membrane.  
4. After blocking, the blot was incubated overnight at 4ºC with respective primary 
antibody. The primary antibody was prepared in 5% bovine serum albumin in 1X 
tris buffer saline (TBS) buffer.  
5. The next morning the blot was washed thrice with TBS before adding HRP 
conjugated secondary antibody specific for the primary antibody. The blot was then 
incubated at room temperature for 2 hour in a shaker. 
6. The blot was again washed thrice with TBS before adding substrate (#1705060-
Clarity Western ECL Substrate, Bio-rad).    
7. Chemiluminescence signals from the immune blot membrane were detected using 
Chemi Doc XRS system, Bio-Rad after adding the substrate.  
The images were captured using Quantity one 1-D analysis software provided by Bio-
Rad and the band intensity was then analyzed using Image J software. The following 
antibodies were used for the detection of ICAM-1 and VCAM-1. The protein levels 
were normalized to GAPDH protein levels in all the experiments.   
a. Anti- ICAM-1 rabbit polyclonal antibody (4915S, Cell signaling technology),  
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b. Anti-VCAM-1 rabbitmonoclonal antibody (13662S, Cell signaling technology)  
c. Monoclonal GAPDH antibody (Santa Cruz, USA).  
Statistical Analysis: 
All the results are expressed as mean ± SD (n= 8-10). One way ANOVA, followed by 
Dunnett’s post hoc test was performed to show the significance of the test results. 
p<0.05 was considered to be statistically significant. 
Results: 
Acute Oral Toxicity Study 
Cage side observations: 
As first animal administered with 175mg/kg of PCM survived for 24 hours, second animal was 
administered with 550mg/kg on next day. After 24, as no mortality were noted, third animal 
was administered with 2000mg/kg on third day. Other two animals were administered 
2000mg/kg on fourth day and fifth day respectively as the third animal survived for 48 
hours.However, the third animal administered with of 2000 mg/kg dose died 4 days after PCM 
administration with decline in feed consumption (0-2%) from 3rd day. 
 
Figure 4. 1: Acute toxicity study: Feed weight with respect to body weight 
      Feed consumption with respect to body weight of male animals are expressed in 
percentage and is shown in Figure 4.1. Average feed consumption of control and 175 
mg/kg is about 8-10 %. 550 mg/kg drug administered animal consumes an average of    
6-8%. 2000 mg/kg drug administered animal consumption declines initially up to day 
5 with an average of 5-1% and increases to 7-10%. An animal with 2000 mg/kg dose 
died on day 3 with minimum feed consumption of 0-2%. 
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Figure 4. 2: Acute toxicity study: Body weight of animals 
 
The body weight of the study animals were expressed in percentage is shown in Figure 
4.2. The control and 175 mg/kg dose administered animal maintains an average of 13% 
and 5% respectively. The 550 mg/kg dosed animal maintains till the last with minimum 
reduction of 2-3%. The 2000 mg/kg dosed animal shows decline with 10-25% up to 
day 6 and gradually increases with 5-10%. An animal of 2000 mg/kg dose died on day3 
with a reduction of 10% in body weight. 
Organ weight: 
 
Figure 4. 3: The weight of brain of acute toxicity study animals in percentage. 
The weight of brain of the study animals with respect to their body weight is shown in 
Figure 4.3. There is no significance noted when compared with control because of the 
sample size (n=1).  
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Figure 4. 4: The weight of heart of acute toxicity study animals in percentage. 
The weight of heart of the study animals with respect to their body weight is shown in 
Figure 4.4. There is no significance noted when compared with control because of the 
sample size (n=1).  
 
Figure 4. 5: The weight of liver of acute toxicity study animals in percentage. 
The weight of liver of the study animals with respect to their body weight is shown in 
Figure 4.5. There is no significance noted when compared with control because of the 
sample size (n=1).  
 
Figure 4. 6: The weight of spleen of acute toxicity study animals in percentage. 
The weight of spleen of the study animals with respect to their body weight is shown 
in Figure 4.6. There is no significance noted when compared with control because of 
the sample size (n=1).  
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Figure 4. 7: The weight of thymus of acute toxicity study animals in percentage. 
The weight of thymus of the study animals with respect to their body weight is shown 
in Figure 4.7. There is no significance noted when compared with control because of 
the sample size (n=1).  
 
Figure 4. 8:  The weight of kidney of acute toxicity study animals in percentage. 
The weight of kidney of the study animals with respect to their body weight is shown 
in Figure 4.8. There is no significance noted when compared with control because of 
the sample size (n=1).  
 
Figure 4. 9: The weight of adrenal gland of acute toxicity study animals in percentage. 
The weight of adrenal gland of the study animals with respect to their body weight is 
shown in Figure 4.9. There is no significance noted when compared with control 
because of the sample size (n=1).  
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Figure 4. 10: The weight of uterus of acute toxicity study animals in percentage. 
The weight of uterus of the study animals with respect to their body weight is shown in 
Figure 4.10. There is no significance noted when compared with control because of the 
sample size (n=1).  
 
Figure 4. 11: The weight of ovary of acute toxicity study animals in percentage. 
The weight of ovary of the study animals with respect to their body weight is shown in 
Figure 4.11. There is no significance noted when compared with control because of the 
sample size (n=1).  
Gross pathology: 
An animal of 2000 mg/kg dose showed significant reduction in spleen size. All the three 
animals administered with 2000mg/kg showed rough impressions on the surface of 
kidney. Other than this observation, no changes were noted in gross pathology. 
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Sub-Acute Toxicity: 
Mortality and Morbidity: 
Among the 70 animals, 13 animals were dead before the completion of the study. 
Among the 13 animals 12 were mortal and 1 was moribund. The death details are given 
in table 4.2. 
Table 4. 2 Intermediate death details of the animals in 28 days repeated oral toxicity study. 
Day of death Group of dead animal Sex Death details 
3 Satellite high dose Male Mortal 
4 High dose Male Mortal 
4 High dose Male Mortal 
4 Satellite high dose Male Mortal 
4 Satellite high dose Male Morbid 
4 Satellite high dose Male Morbid 
4 Satellite high dose Male Mortal 
4 High dose Male Mortal 
4 High dose Male Mortal 
4 High dose Female Morbid 
6 Satellite high dose Female Mortal 
8 Medium dose Male Mortal 
12 Satellite high dose Female Morbid 
Cage side observations: 
Various abnormal observations were noted in animals treated with various doses of 
PCM. They are depicted below. 
Pin point pupil: 
All the animals that died in between the study period showed pin point pupil for a few 
hours before death. Pin point pupil was more expressed in male animals compared with 
female animals. However, this could not be noticed in all other animals that survived 
the entire study period. (Shown in fig. 4.12). 
Intentional tremor: 
All the animals that died in between the study period showed intentional tremor for a 
period of few hours to few days before death. Tremor was more expressed in male 
animals compared with female animals. However, tremor could not be noticed in all 
other animals that survived the entire study period.  
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Figure 4. 12: A high dose treated female animal showing pin point pupil before death 
Gait: 
Moreover, animals were partially paralysed when they started expressing tremors. A 
typical tip toe walking pattern is observed in all the animals before death (shown in 
fig.4.13).  
 
Figure 4. 13: high dose treated female animal showing tiptoe walking before death 
Piloerection: 
All the animals that died in between the study period showed piloerection from one day 
after drug administration.Piloerection was equally expressed in male animals and 
female animals. Moreover, all the animals of medium drug treated groups showed 
Piloerection up to two weeks and gradually recovered after that. Piloerection could not 
be noticed in all other groups (low dose, vehicle control and normal control) that 
survived the entire study period. (Shown in fig. 4.14). 
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Figure 4. 14: A high dose treated female animal showing piloerection 
 
 
Figure 4. 15: A medium dose treated male animal showing testicular hypertrophy 
Testicular hypertrophy: 
Two animals of the medium dose treated male animals showed testicular hypertrophy 
from 6-8 days that recovered within 2 days. However, Testicular hypertrophy could not 
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be noticed in mortal/moribund animals and all other group animals that survived the 
entire study period. (Shown in fig. 4.15) 
 
Figure 4. 16: A medium dose treated male animal showing splenomegaly 
Splenomegaly: 
Splenomegaly is not observed in any of the mortal/moribund animals. But it is very 
prominent in all other high dose and medium dose treated male and female animals that 
survived the entire study period during second week of the study. Splenomegaly 
recovered in 3-4 days in all the affected animals. Low dose, vehicle control and high 
dose treated animals did not show any splenomegaly. (shown in figure.4.16). 
The abnormal behavioural changes were observed and graphed in Figure 4.17 with 
respect to the obtained cumulative score of the study animals.  
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Figure 4. 17: The abnormal behavioral changes of the study animals were presented in the 
form of cumulative score. 
Feed weight: 
Feed consumption with respect to body weight of male and female animals are 
expressed in percentage and is shown in Figure.4.18 and figure 4.19 respectively. 
 
Figure 4. 18:28-repeated toxicity study: Feed consumption with respect to body weight of male 
animals. n=3-5 in all groups except in high dose (n=1). 
 
 
Figure 4. 19: 28-repeated toxicity study: Feed consumption with respect to body weight of 
femaleanimals. (n=3-5) 
The average feed consumption in normal and vehicle control group range between 9-
12percentage. All other groups showed a significant decline in feed consumption up to 
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day 8 but weresimilar to control group from day 9. But in high dose, significant 
difference could not made out because of low sample size (n=1). 
 
 
Figure 4. 20: 28-repeated toxicity study: Feed consumption with respect to bodyweight of 
satellite group female animals. n=3-5 in all groups. 
Feed consumption with respect to body weight of satellite group animals are expressed 
in percentage and is shown in Figure.4.20.The feed consumption was identical to the 
observations in drug administered groups. 
 
Figure 4. 21:Body weight of male animals in percentage. n=3-5 in all groups except in high 
dose (n=1). 
The increase in body weight of male animals were expressed in percentage and is shown 
in Figure.4.21.  
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Figure 4. 22: Body weight of female animals in percentage. n=3-5 in all groups. 
Thenormal and vehicle control group shows an increase of 60-65% from initial body 
weight. In low and medium dose groups, there is an initial reduction till day 3 followed 
by gradual increase up to 45%. In high dose, one animal survives till last day of study 
and shows reduction in weight initially followed by an increase up to 60%.  
The increase in body weight of female animals was expressed in percentage and is 
shown in Figure. 4.22. Thenormal and vehicle control group shows an increase of 35-
40% from initial body weight. In low dose group, there is a gradual increase from the 
initial day and shows 40% increase. In medium and high dose groups, there is initial 
reduction till day 3 followed by gradual increase up to 35%.  
 
Figure 4. 23: Body weight of female animals in percentage. n=3-5 in all groups. 
The increase in body weight of female satellite group animals were expressed in 
percentage and is shown in Figure.4.23. Thecontrol group shows an increase of 50-52% 
from initial body weight. In satellite high dose group, there is an initial reduction till 
day 5 followed by gradual increase and reaches 50% of increase at the end of study. 
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Organ weight: 
 
Figure 4. 24: Weight of brain of study animals with respect to the body weight. **** p <0.01. 
n=3-5 in all groups except Male High dose group (n=1) and Female intermediate death (n=2) 
The weight of brain in male and female animals are expressed in percentage with 
respect to the individual body weight and is shown in Figure 4.24. There is a significant 
increase of 30% in male high dose intermediate death group when compared with 
normal control. Although the female high dose intermediate death group shows 60% 
increase, but the sample size is low and that the statistical significance could not be 
made out.  
 
Figure 4. 25: Weight of heart of study animals with respect to the body weight. **** p <0.01. 
n=3-5 in all groups except Male High dose group (n=1) and Female intermediate death (n=2). 
The weight of heart in male and female animals are expressed in percentage with 
respect to the individual body weight and is shown in Figure 4.25. There is a significant 
increase of 15% in male high dose intermediate death group when compared with 
normal control group. 
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Figure 4. 26: Weight of liver of study animals with respect to the body weight. . **** p <0.01. 
n=3-5 in all groups except Male High dose group (n=1) and Female intermediate death (n=2) 
The weight of liver in male and female animal groups are expressed in percentage with 
respect to the individual body weight is shown in Figure 4.26. This shows that there is 
a significant increase in intermediate death of high and satellite high dose treated male 
animals. 
 
Figure 4. 27: Weight of spleen of study animals with respect to the body weight. . *** p <0.05. 
n=3-5 in all groups except Male High dose group (n=1) and Female intermediate death (n=2). 
The weight of spleen in male and female animals are expressed in percentage with 
respect to the individual body weight and is shown in Figure 4.27. There is a significant 
reduction of 20% in male high dose intermediate death group when compared to normal 
control group. 
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Figure 4. 28:Weight of thymus of study animals with respect to the body weight. . **** p 
<0.01. n=3-5 in all groups except Male High dose group (n=1) and Female intermediate death 
(n=2). 
The weight of thymus in male and female animals are expressed in percentage with 
respect to the individual body weight and is shown in Figure 4.28. There is no 
significant difference among the groups. 
The weight of kidney in male and female animals are expressed in percentage with 
respect to the individual body weight and is shown in Figure 4.29. There is a significant 
increase of 40%, 60% in male medium dose and male high dose intermediate death and  
30%, 50% and 40% in female low dose, medium dose and high dose group respectively. 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
N.Control V.Control L.Dose M.dose H.dose H.D interm
death
Sat.Control Sat. H.D
P
er
ce
n
ta
g
e 
o
f 
w
ei
g
h
t(
%
)
Animal Groups
Male Female
 64 Pre-clinical experiments 
 
Figure 4. 29: Weight of kidney of study animals with respect to the body weight. . **** p 
<0.01. n=3-5 in all groups except Male High dose group (n=1) and Female intermediate death 
(n=2). 
 
Figure 4. 30: Weight of adrenal gland of study animals with respect to the body weight. . **** 
p <0.01. n=3-5 in all groups except Male High dose group (n=1) and Female intermediate 
death (n=2). 
The weight of adrenal gland in male and female animals are expressed in percentage 
with respect to the individual body weight and is shown in Figure 4.30. There is a 
significant increase of 1.5% inmale high dose intermediate death group when compared 
with normal control. 
 
Figure 4. 31: Weight of testis of study animals with respect to the body weight. . **** p <0.01. 
n=3-5 in all groups except Male High dose group (n=1). 
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The weight of testis in male animal group are expressed in percentage with respect to 
the individual body weight and is shown in Figure 4.31. No significant difference is 
observed among the groups. 
 
 
Figure 4. 32: Weight of epididymis of study animals with respect to the body weight. . **** p 
<0.01. n=3-5 in all groups except Male High dose group (n=1). 
The weight of epididymis in male animal group are expressed in percentage with 
respect to the individual body weight and is shown in Figure 4.32.  There is a significant 
14% reduction in male high dose intermediate death group when compared with normal 
control. 
 
Figure 4. 33: Weight of uterus of study animals with respect to the body weight. . **** p <0.01. 
n=3-5 in all groups except High dose intermediate death group (n=2). 
The weight of uterus in female animals are expressed in percentage with respect to the 
individual body weight and is shown in Figure 4.33. There is no significant difference 
between groups. 
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Figure 4. 34: Weight of ovary of study animals with respect to the body weight. . **** p <0.01. 
n=3-5 in all groups except High dose intermediate death group (n=2). 
The weight of ovary in female animals are expressed in percentage with respect to the 
individual body weight and is shown in Figure 4.34. There is no significant difference 
between groups. 
Haematology Analysis:  
 
Figure 4. 35: The effect of PCM on WBC in 28-days repeated oral toxicity study animals. 
The total count of white blood cells in 28-days repeated oral toxicitystudy animals is 
shown in Figure 4.35. No significant difference could be noted in any groups compared 
with normal control. 
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Figure 4. 36: The effect of PCM on Neutrophil in 28-days repeated oral toxicity study animals. 
The percentage of neutrophil in 28-days repeated oral toxicitystudy animals is shown 
in Figure 4. 36. No significant difference could be noted in any groups compared with 
normal control. 
 
Figure 4. 37: The effect of PCM on Lymphocytes in 28-days repeated oral toxicity study 
animals. 
The percentage of lymphocytes in 28-days repeated oral toxicitystudy animals is shown 
in Figure 4. 37. No significant difference could be noted in any groups compared with 
normal control. 
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Figure 4. 38: The effect of PCM on Monocytes in 28-days repeated oral toxicity study animals. 
The percentage of monocytes in 28-days repeated oral toxicitystudy animals is shown 
in Figure 4. 38. Monocyte count was significantly increased in medium dose and high 
dose treated male animals. No significant difference could be noted in any groups 
compared with normal control. 
 
 
Figure 4. 39: The effect of PCM on Eosinophil in 28-days repeated oral toxicity study animals. 
The percentage of Eosinophil in 28-days repeated oral toxicitystudy animals is shown 
in Figure 4. 39. Eosinophil count was significantly increased in high dose treated male 
animals. No significant difference could be noted in any other groups compared with 
normal control. 
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Figure 4. 40: The effect of PCM on Basophil in 28-days repeated oral toxicity study animals. 
The percentage of Basophil in 28-days repeated oral toxicitystudy animals is shown in 
Figure 4. 40. Basophil count was significantly increased in high dose treated male 
animals. No significant difference could be noted in any other groups compared with 
normal control. 
 
 
Figure 4. 41: The effect of PCM on Neutrophil in 28-days repeated oral toxicity study animals. 
The total count of Neutrophil in 28-days repeated oral toxicitystudy animals is shown 
in Figure 4. 41. No significant difference could be noted in any other groups compared 
with normal control. 
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Figure 4. 42: The effect of PCM on Lymphocyte in 28-days repeated oral toxicity study 
animals. 
The total count of Lymphocyte in 28-days repeated oral toxicity study animals is shown 
in Figure 4. 42. Lymphocyte count was significantly decreased in medium dose treated 
male animals. No significant difference could be noted in any other groups compared 
with normal control. 
 
 
Figure 4. 43: The effect of PCM on Monocyte in 28-days repeated oral toxicity study animals. 
The total amount of Lymphocyte in 28-days repeated oral toxicity study animals is 
shown in Figure 4. 43. Lymphocyte count was significantly decreased in medium dose 
treated male animals. No significant difference could be noted in any other groups 
compared with normal control. 
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Figure 4. 44: The effect of PCM on Eosinophil in 28-days repeated oral toxicity study animals. 
The total count of Eosinophil in 28-days repeated oral toxicity study animals is shown 
in Figure 4. 44. Eosinophil count was significantly increased in dose treated male 
animals. No significant difference could be noted in any other groups compared with 
normal control.
 
Figure 4. 45: The effect of PCM on Basophil in 28-days repeated oral toxicity study animals. 
The total count of Basophil in 28-days repeated oral toxicitystudy animals is shown in 
Figure 4.45. Basophil count was significantly decreased in medium dose treated male 
animals. No significant difference could be noted in any other groups compared with 
normal control. 
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Figure 4. 46: The effect of PCM on RBC in 28-days repeated oral toxicity study animals. 
The total count of Red blood cells in 28-days repeated oral toxicity study animals is 
shown in Figure 4.46. No significant difference could be noted in any groups compared 
with normal control. 
 
 
Figure 4. 47: The effect of PCM on Hemoglobin in 28-days repeated oral toxicity study 
animals. 
The total amount of Hemoglobin 28-days repeated oral toxicity is study animals shown 
in Figure 4.47. No significant difference could be noted in any groups compared with 
normal control. 
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Figure 4. 48: The effect of PCM on Hematocrit value in 28-days repeated oral toxicity study 
animals. 
The total amount of Hemoglobin in 28-days repeated oral toxicitystudy animals is 
shown in Figure 4.48. No significant difference could be noted in any groups compared 
with normal control. 
 
 
Figure 4. 49: The effect of PCM on MCV in 28-days repeated oral toxicity study animals. 
The total amount of MCV in 28-days repeated oral toxicity study animals is shown in 
Figure 4.49. No significant difference could be noted in any groups compared with 
normal control. 
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Figure 4. 50: The effect of PCM on MCH in 28-days repeated oral toxicity study animals. 
The total amount of MCHin 28-days repeated oral toxicity study animals is shown in 
Figure 4.50. No significant difference could be noted in any groups compared with 
normal control. 
 
 
Figure 4. 51: The effect of PCM on MCHC in 28-days repeated oral toxicity study animals. 
The total amount of MCHCin 28-days repeated oral toxicity study animals is shown in 
Figure 4.51. No significant difference could be noted in any groups compared with 
normal control. 
The total amount of RDWCVin 28-days repeated oral toxicity study animals is shown 
in Figure 4.52. No significant difference could be noted in any groups compared with 
normal control. 
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Figure 4. 52: The effect of PCM on RBC distribution width (C.V)in 28-days repeated oral 
toxicity study animals. 
 
Figure 4. 53: The effect of PCM on RBC distribution width (S.D) in 28-days repeated oral 
toxicity study animals. 
The total amount of RDWSDin 28-days repeated oral toxicity study animals is shown 
in Figure 4.53. No significant difference could be noted in any groups compared with 
normal control. 
 
 
Figure 4. 54: The effect of PCM on Platelets in 28-days repeated oral toxicity study animals. 
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The total amount of Platelets in 28-days repeated oral toxicity study animals is shown 
in Figure 4.54. No significant difference could be noted in any groups compared with 
normal control. 
 
Figure 4. 55: The effect of PCM on MPV in 28-days repeated oral toxicity study animals. 
The mean platelet volume in 28-days repeated oral toxicity study animals is shown in 
Figure 4.55. No significant difference could be noted in any groups compared with 
normal control. 
 
 
Figure 4. 56: The effect of PCM on PDW in 28-days repeated oral toxicity study animals. 
The total amount of PDW in 28-days repeated oral toxicity study animals is shown in 
Figure 4.56. No significant difference could be noted in any groups compared with 
normal control. 
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Figure 4. 57: The effect of PCM on Plateletcrit in 28-days repeated oral toxicity study animals. 
The total amount of Plateletcritin 28-days repeated oral toxicity study animals is shown 
in Figure 4.57. No significant difference could be noted in any groups compared with 
normal control. 
Bio-chemical Analysis: 
Effect of PCM on various bio-chemical parameters that regulate liver and renal 
functions is shown in table 4.3, table 4.4, table 4.5 and table 4.6. Bio-chemical analysis 
could not be performed in mortal and moribund animals.  
Table 4. 3: The effect of PCM on various liver function parameters in male animals of 28 days 
repeated oral toxicity study. n = 1 in high dose and 4-5 in all other groups ; *P<0.05 
Group SGOT ALP SGPT T.billirubin D.bilirubin BUN 
Control 21.5±4.4 111.7±25.9 43.5±23.5 1.3±0.7 0.7±0.1 24.7±8.3 
Vehicle control  28.1±9.9 107.25±18.6 7.2±1.8 0.4±0.2 0.5±0.2 37.9±1.0 
Low dose 19.1±4.1 110±7.9 14.5±4.5 0.2±0.0 0.7±0.2 19.6±7.9 
Medium dose 24.3±12.9 93.96±20.6 93.3±33.7 43.7±15.8 0.2±0.0 0.4±0.2 
High dose 13.96 31.17 64.26 30.08 3.19 0.0 
No significant difference was noted in the levels of SGOT, SGPT, ALP, blood urea 
nitrogen, total and direct bilirubin levels in all the PCM treated male animalswhen 
compared with the normal control group. 
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Table 4. 4: The effect of PCM on various renal function parameters in male animals of 28 days 
repeated oral toxicity study.n = 1 in high dose and 4-5 in all other groups ; *P<0.05 
Group Albumin Cholesterol Protein Uric acid Creatinine Urea 
Control 3.8 ±0.12 210.22±57.8 9.0±0.6 5.1±0.7 0.5±0.3 52.7±17.8 
Vehicle control  3.4±.08 276.5±72.7 9.3±0.7 3.2±0.02 0.4±0.5 81.0±2.1 
Low dose 3.6±0.08 261.8±61.7 8.0±0.1 3.4±0.3* 0.5±0.05 41.8±16.9 
Medium dose 3.6±0.04 127.3±13.4 8.0±0.2 3.5±0.05* 0.5±0.05 93.3±33.7 
High dose 3.2 563.6 7.6 4.8 0.4 64.3 
No significant difference was noted in the levels of albumin, cholesterol, protein, uric 
acid, creatinine and urea levels in all the PCM treated male animals when compared 
with the normal control group. 
Table 4. 5: The effect of PCM on various liver function parameters in female animals of 28 
days repeated oral toxicity study.n = 4-5 in all other groups ; *P<0.05 
Group SGOT ALP BUN SGPT T.billirubin D.bilirubin 
Control 36.82±11.2 72.42±14.06 35.38±5.3 6.83±1.5 0.02±0.015 0.65±0.1 
Vehicle 
control  
15.20±3.5 60.5±12.9 28.14±12.4 7.21±2.1 0.023±0.003 0.31±0.2 
Low dose 50.02±13.5 77.31±4.4 21.23±7.9 22.68±18.3 0.012±0.01 0.65±0.09 
Medium 
dose 
15.65±1.3 101.98±14.0 26.67±9.9 20.8±9.08 0.0240±0.01 0.21±0.2 
High dose 38.01±28.8 91.67±12.1 31.75±13.7 12.8±6.4 0.27±0.009 0.29±0.08 
Sat. Control 16.17±0.9 136.77±20.6 24.25±3.6 6.9±0.65 0.46±2 0.9±0.4 
Sat. High 
dose 
14.35±2.4 146.7±12 30.6±18.9 10.3±5.02 0.3±0.2 1.9 
No significant difference was noted in the levels of SGOT, SGPT, ALP, blood urea 
nitrogen, total and direct bilirubin levels in all the PCM treated female animalswhen 
compared with the normal control group. 
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Table 4. 6: The effect of PCM on various renal function parameters in female animals of 28 
days repeated oral toxicity study.n = 4-5 in all other groups ; *P<0.05 
Group Albumin Cholesterol Protein Uric acid Creatinine Urea 
Control 3.49±0.08 233.04±71.5 8.32±0.2 4.39±0.6 0.48±0.07 45.24±19.08 
Vehicle control  3.52±0.03 173.06±26.7 8.52±0.1 3.36±0.1 0.58±0.08 89.28±3.1 
Low dose 3.27±0.02 127.22±9.9 7.65±0.3 3.96±0.1 0.38±0.0 45.36±16.8 
Medium dose 3.4±0.12 180.17±34.7 7.10±0.2 3.90±0.2 0.5±0.0 64.4±21.1 
High dose 3.68±0.3 279.15±110.8 7.31±0.5 3.37±0.6 0.41±0.1 51.34±26.5 
Sat. Control 12.23±3.2 141.45±2.7 12.5±0.1 3.52±0.6 0.33±0.03 51.8±7.7 
Sat. High dose 17.32±2.7 129.8±9.9 9.16±0.6* 19.65±12 0.33±0.04 65.3±40.3 
 
No significant difference was noted in the levels of albumin, cholesterol, protein, uric 
acid, creatinine and urea levels in all the PCM treated male animalswhen compared 
with the normal control group. 
Gross pathology: 
 Mortal and moribund showed a significant reduction in size of spleen and 
epididymis (3 times). In most of the mortal and moribund animals inflammation in 
spleen and kidneys are noted. 
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Histopathology: 
 
 
Figure 4. 58: Representative images histopathology of kidney of A) Normal control male 
animals B) High dose treated male animal C) Normal control female animals and D) High dose 
treated female animal. Images are shown at 40X magnification 
Representative images of tissue sections of kidney are shown in Fig. 4.58. Marked 
multifocal, bilateral degeneration/necrotic changes of tubular, noted in male and female 
animals of high dose PCM treated group compared with normal control. 
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Figure 4. 59: Representative images histopathology of colon of A) Normal control male 
animals B) High dose treated male animal C) Normal control female animals and D) High dose 
treated female animal. Images are shown at 40X magnification 
Representative images of tissue sections of colon are shown in Fig. 4.59. Moderate 
mononuclear mucosal infiltrates are noted in high dose PCM treated group compared 
with normal control.  
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Figure 4. 60: Representative images histopathology of brain of A) Normal control male 
animals B) High dose treated male animal C) Normal control female animals and D) High dose 
treated female animal. Images are shown at 40X magnification 
Representative images of tissue sections of brain are shown in Fig. 4.60. No 
pathological changes could be observed in brain of high dose treated animals compared 
with normal control of male and female animals. 
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Figure 4. 61: Representative images histopathology of liver of A) Normal control male animals 
B) High dose treated male animal C) Normal control female animals and D) High dose treated 
female animal. Images are shown at 40X magnification 
Representative images of tissue sections of liver are shown in Fig. 4.61. No significant 
abnormality in liver tissues could be noted in high dose treated animals when compared 
with normal control male and female animals. 
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Figure 4. 62: Representative images histopathology of epididymis of A) Normal control male 
animals B) High dose treated male animal. Images are shown at 40X magnification 
Representative images of tissue sections of epididymis are shown in Fig. 4.62. No 
significant abnormality in epididymis could be noted in high dose treated animals when 
compared with normal control male animals. 
 
Figure 4. 63: Representative images histopathology of ovary of A) Normal control female 
animals B) High dose treated female animal. Images are shown at 40X magnification 
Representative images of tissue sections of ovary are shown in Fig. 4.63. No significant 
abnormality could be noted in ovary of high dose treated animals when compared with 
normal control female animals. 
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Western blotting: 
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Figure 4. 64: The expression of V-CAM-1 protein in Kidney of PCM treated study animals. 
 
The expressionof V-CAM-1 protein in kidney of the PCM treated study animals were 
shown in Figure.4.64. This shows that there is a decrease of V-CAM-1 protein 
expression in high dose treated animals. 
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Figure 4. 65 : The expression of I-CAM-1 protein in Kidney of PCM treated study animals. 
The expressionof I-CAM-1 protein in kidney of the PCM treated study animals were 
shown in Figure.4.65. This shows that there is a significant decrease of I-CAM-1 
protein expression in high dose treated animals. 
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Figure 4. 66: The expression of V-CAM-1 protein in Spleen of PCM treated study animals. 
The expressionof V-CAM-1 protein in Spleen of the PCM treated study animals were 
shown in Figure.4.66. This shows that there is a signicant decrease of V-CAM-1 protein 
expression in low dose treated animals. 
Discussion: 
The major perspective of this work is to understand the effect of PCM in short term and 
long term oral administration at different dose. For single oral administration, dosing 
was performed as per OECD guidelines. For sub-acute toxicity, animal therapeutic dose 
(20mg/kg) was calculated from human therapeutic dose and was fixed as low dose. Five 
times the animal therapeutic dose is fixed as medium dose (100mg/kg) and ten times 
the animal therapeutic dose (200mg/kg) is fixed as high dose.  
Acute oral toxicity study: 
Single oral administration of PCM produced delayed toxicity in the animals 
administered with dose of  550mg/kg body weight (which is more than 25 times that of 
therapeutic dose) and above. Mortality is seen in one of the three animals administered 
with 2000mg/kg  Reduction in body weight and feed consumption for the first 7 days 
could be either due to gastric irritation or systemic inflammation. Death of one animal 
administered with 2000mg/kg bodyweight on the 4th day indicated that, a single dose 
of PCM could be lethal at high doses. As the autopsy data of the dead animal is not 
available, the cause of death could not be clearly established. However, it could be 
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presumed that systemic inflammation followed by multiple organ failure could be a 
plausible reason as evidenced from significant loss of weight following administration. 
Increase in size of kidney and brain of animals administered with 2000mg/kg vouches 
the presence of systemic inflammation. 
Sub-acute toxicity: 
In sub-acute study, no significant toxicity could be observed at therapeutic doses 
in male and female animals. However, one mortality is noted among the 20 animals 
administered with five times the therapeutic dose.  
Maximum number of deaths were noted on 4th day with three animals surviving 
up to 6th, 8th and 10th day. Previous reports on toxicity of various forms of mercury 
describe that oral consumption of 20mg/kg of methyl/inorganic mercury produced 
lethality on 2nd day in male animals (75)(76)and females remain unaffected.However, 
in our study, PCM did not produce significant lethal effect at 20mg/kg (low dose – no 
mortality) and 100mg/kg (medium dose – one mortality at 8th day) which signifies that 
the toxic effect of PCM is five times lower than that of the inorganic or organic form 
of mercury. Male female death ratio of 10:3, (1 medium dose, 4 high dose and 5 satellite 
high dose Male animals Vs 1 high dose and 2 satellite high dose animals) in 
mortal/moribund animals convey that males are more sensitivity to toxic effects of 
PCM compared with female animals. This disparity in effect of PCM between male and 
female rats could be ascribed to various mechanisms.The whole-body clearance of 
organic and inorganic mercury in female rats are proved to be faster in females than in 
males(77). As a consequence of this, greater developmental effects are noted in male 
animals than in females(78)(79)(80) proposed that the greater susceptibility of the male 
rat to the acute toxic effects of mercuric chloride may be due to the greater number of 
sulfhydryl groups in the kidneys of males as compared with females. As mercury ions 
have an affinity for the sulfhydryl groups of active sites in some enzymes, such as 
pyruvate kinase (75), a lower number of sulfhydryl groups may protect vital 
components of the cell such as coenzyme A from the effects of mercuric chloride (81). 
Quite different from Muraoka’s work,María H. Hazelhoff et al(82), described that 
gender differences in the rat renal cortical Oat1 and Oat3 appear after puberty and 
demonstrated that the lower Oat1 and Oat3 expression in kidney from female rats 
restricts Hg uptake into renal cells, protecting them from this metal toxicity concluding 
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that Oat1 and Oat3 are among the main transporters responsible for HgCl2-induced 
renal injury(82). 
 
All the animals that died in between showed piloerection, intentional tremors, paralysis, 
hypothermia, tip toe walking and pin point pupil before death. Presence of intentional 
tremors and tip toe walking can either be due to defect in the chief organs controlling 
co-ordination movements (cerebellum and brain stem) or could be a muscle twitching 
or cramping in the legs and/or arms (83) secondary to changes in electrolyte balance 
(i.e., potassium imbalance due to fluid loss or renal wasting). Toxic effects observed in 
Iraqis poisoned by consumption of mercury contaminatedfood grains resulted inloss of 
power in the legs, difficulty in walking, cerebellar ataxia, disturbance of speech, 
paraplegia, or general spasticity, ankle clonus and intentional tremors(84). 
Fasciculation and coarse twitching were also present. It is likely that these effects were 
secondary to effects on the nervous system.Though the pattern of mercury deposits by 
oral ingestion of inorganic mercury markedly vary from region to region within the 
brain, there was a clear tendency for mercury to get heavily accumulated in 
regionsprimarily concerned with motor systems in the brain stem and cerebellum(e.g., 
red nucleus, cranial nerve motor nuclei, deep nuclei of cerebellum)(85). 
Mercuric ions have a very high affinity for thiol-containing biomolecules, such as 
glutathione (GSH), cysteine (Cys), homocysteine (Hcy), N-acetylcysteine (NAC), 
metallothionein (MT) and albumin(86). Hence in biological systems, they are always 
bound to one or more of these compounds and does not exist in an unbound ionic state 
(87). In 1988, Aschner and Clarkson hypothesised that organic mercury may be 
transported from the blood to the CNS across the blood-brain barrier by the L-type 
neutral amino acid carrier transport (LAT) system. A few years later, Kerper et al(88) 
observed that organic mercury entered the rat brain as a cysteine complex via the LAT 
system. A decade later, it was found that LAT1, was associated with increased uptake 
of organic mercury in the presence of L-cysteine (89). These observations culminated 
in the conclusion that Hg-L-cysteine conjugate is a substrate for the LAT1 system, 
which actively transports Hg across membranes and is at least partly responsible, for 
the high Hg levels found in the brain after exposures.Indeed, although other transporters 
have been reported to contribute to MeHg transport (90), LAT1 seems to be the main, 
if not the only, transporter responsible for Hg transport from peripheral tissues to the 
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CNS (88). As no previous studies regarding musculoskeletal effects in animals after 
oral exposure to inorganic mercury could be located, this could not be conclusively 
established.  
A gradual weight loss and decrease in feed in take noted in initial stage of study 
(up to 8 day) in all animals (low, medium and high dose) administered with PCM rats 
indicates its effect in intestinal enterocytes. Ithasbeensuggestedthat the means by which 
mercury is transported across intestinal enterocytes depends upon the species of 
mercury present in the intestinal lumen, which itself is dependent upon the ligands 
available to which mercury can bind (91).Considering the abundance of amino acid 
transporters in the luminal plasma membrane of enterocytes and evidencesof amino 
acid and/ or peptide transporters significant roles in the intestinal absorption of 
mercury, it is likely that Aṇṭatailam, (a rich source of glutathione and other amino acids) 
present in PCM would have favoured the intestinal absorption of PCM. However, small 
amount of mercury may be taken up following ligand exchange whereby a mercuric 
ion is removed from its thiol carrier and is taken up bydivalent metal transporter 1 
(DMT1 -An ion transporter localized in the apical membrane of enterocytes). This 
would have caused theaccumulation of mercury inside enterocytes (as mercury can be 
transported out only as a thiol conjugate) resulting in enteritis followed by decreased 
feed intake and reduction in body weight. Later, either due to the increased production 
of thiol-containing proteins due to activation of MTF genes or from external thiol 
sources, the accumulated mercury would have been secreted out resulting in resolving 
of the enteritis. As both methyl and inorganic mercury can be transported out of 
intestine, kidney, and probably other cells on the glutathione carrier, his molecular 
mimicry between mercury thiol complexes and endogenous substrates of transport 
carriers gives useful insights into key aspects of mercury toxicology. 
Conclusion: 
 In single dose oral administration, PCM did not show any lethal effect up to 550 
mg/kg. 
 In single dose oral administration, PCM did not show any toxicity at 175 mg/kg 
which is approximately more than 8 times of the therapeutic dose. Mild changes 
in feed consumption and body weight was noted in animal administered with 
550 mg/kg. 
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 One among the three animals administered with 2000 mg/kg (100 times of the 
therapeutic dose) died on the 4thday indicating the lethal effect of PCM at very 
high doses. 
 On repeated oral administration, PCM was found to be highly lethal at 10 times 
the therapeutic dose.  
 Lethality was found to be 3 times higher in male compared with female possibly 
due to the over expression of OAT 1 and OAT 2 in kidneys or the influence of 
male hormones. 
 Only one among the 20 animals, died on the 8th day in repeated administration 
of PCM at the 5 times the therapeutic dose (medium dose) signifying that PCM 
can be sensitive to specific individuals at medium doses. 
 In all the morbid animals, neurotoxicity and musculoskeletal toxicity were 
observed before death signifying the toxic effect of PCM in brain at higher 
doses. However the confirmation can be made only after determining the 
mercury levels in brain tissues. 
 Testicular toxicity, splenomegaly and nephrotoxicity is also noted in animals 
that were treated with 10 times the therapeutic dose of PCM. 
 Degeneration of nephrons is observed in noted in all the animals administered 
with 10 times the therapeutic dose. 
From this information we conclude that, 
PCM is completely safe in rats at therapeutic doses in repeated oral administration for 
a period of 28 days in rats. Though PCM can be rarely lethal in sensitive males at the 
dose of 5 times that of therapeutic dose, it did not show any significant toxic effect in 
female animals. However, splenomegaly (that resolved within 10 days in repeated dose 
administration) and nephrotoxicity is observed in most of these animals. Severe 
neurotoxic and musculo-toxic effects were noted in all the animals that died during the 
course of study. A clear gender disparity is noted in lethal effects of PCM administered 
at 10 times the therapeutic dose with 3 times high mortality in males compared with 
females. Despite the neurotoxic effects observed in high dose PCM administered rats 
before death, survived animals did not show any neurotoxicity. Instead, nephrotoxicity 
is seen in most of the animals administered with high dose.The difference in toxic 
effects at acute stage and repeated dose administration remains unclear. 
  
 
 
 
 
 
Summary and Conclusion: 
1. The medicine Pañca cūta meḻuku (PCM) referenced in the Siddha literature 
Yūkikarical- 151 was chosen for the dissertation and approved formally by 
institution. 
2. The metal drugs were authenticated by experts in Chemistry department, Siddha 
Central Research Institute, Chennai. 
3. The herbal drugs were authenticated by experts in Herbal garden, Siddha 
Central Research Institute, Mettur dam. 
4. Drug were purified as per the literature and subjected to preparatory procedures. 
5. The medicine PCM was successfully prepared with precautionary measures and 
authenticated. 
6. As per PLIM guidelines standardization parameters and qualitative analysis 
were studied. 
7. FTIR analysis showed the presence of both organic and inorganic substances. 
8. Approximately 95% degradation of PCM at with most of the mercury 
epaporating above 400oC indicated the presence of significant organic form of 
mercury in final PCM 
9. This was substanciated by elememtal analysis, as it showed the decrease in 
percentage of mercury before and after trituration.  
10. Following that XRD was performed to know the speciation of elements in PCB-
before trituration and PCM-FINAL and the inference indicates that the presence 
of HgCl2 and Hg2Cl2 in the former but in latter HgS was the major compound. 
11. One-time oral administration of PCM produced notable toxicity only at very 
high doses (hundred times that of therapeutic dose) and was found to be 
completely safe up to twenty-seven times that of therapeutic dose in female 
animals.  
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12. On continuous administration for a period of Twenty-eight days, PCM was 
found to be safe at therapeutic dose in male and female animals. Though 
mortality was seen at 8th day in one among the 10 male animals administered 
with five times that of therapeutic dose, female animals didn’t show any lethal 
effects.Repeated administration of ten times that of therapeutic dose caused 
mortality in both male and female animals from fourth day. 
13. A clear disparity is seen between male and female animals in mortality rate with 
male death three times more when compared with female animals. This 
disparity could be attributed to the influence of sex in expression of OAT 1 & 
OAT 2 in the renal cell membrane or direct influence of sex hormones.  
14. All the animals that died during the course of study showed neurotoxic or 
musculo-toxic symptoms, whereas the animals that survived the complete 
course of study showed nephrotoxic symptoms. Upregulation of major 
inflammatory markers, ICAM-1 and VCAM-1 in kidney and spleen confirmed 
the active inflammation in both spleen and kidney of high dose administered 
animal 
Future directions: 
This study gave a primary understanding about the safety of PCM at therapeutic doses 
and neurotoxicity, musculotoxicity and nephrotoxicity at high doses. However, the 
exact organs of absorbtion, deposition and excretion was not very clear. The complete 
knowledge on absorbtion of PCM is possible only by performing various 
pharmacokinetic studies with large sample size and evaluation of few physico-chemical 
properties such as zeta potential in various vehicles. Moreover, a study on mercury 
levels in different organs after administration of PCM at various duration is essential to 
understand the deposition of PCM on oral exposure. Though two major proteins of 
inflammatory pathway is analysed in this study, the complete knowledge on effect of 
PCM on various signalling pathways can be obtained only performing protieomics 
study on various interacellular proteins (particularly cell cycle regulator proteins). Once 
we have all these data, we will have a complete contemporary understanding of saftety 
and toxic aspects of PCM.
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